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1. Introduction 
Given that a clear, universal definition of advanced Hodgkin lymphoma does not exist, it 
comes as no surprise that the treatment of this disease is a controversial subject. Currently, 
the cure rate of advanced Hodgkin lymphoma is relatively high, although most physicians 
and patients confronting this disease recognize that the cure rate is less than ideal and the 
costs of treatment are substantial in terms of morbidity and mortality. The current research 
focus in this disease, as with any oncologic disorder, is to maximize the curative potential of 
treatment while minimizing patient suffering.  
In this chapter, the following topics will be discussed: the definition of advanced Hodgkin 
lymphoma, the development of combination chemotherapy for this disease, the important 
clinical trials that led to ABVD (a combination chemotherapy regimen consisting of: 
adriamycin, bleomycin, vinblastine, and dacarbazine) becoming the gold standard, the 
emergence of escalated BEACOPP (a combination chemotherapy regimen consisting of: 
bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and 
prednisone), as a challenger to ABVD therapy, utilization and role of other combination 
chemotherapy regimens, the controversial role of radiotherapy, the roles of autologous and 
allogeneic hematopoietic stem cell transplantation, prognostic factors in both untreated and 
relapsed patients, promising therapies of the future, and case studies.  
As a young physician and investigator, the two most exciting areas of research currently 
involve the use of fusion positron emission tomography/ computed tomography (PET/CT) 
imaging and the continued expansion of targeted treatment strategies, such as brentuximab 
vedotin and rituximab, which will hopefully allow both improved treatment tailoring and 
subsequent outcome for patients.    
2. Definition of “advanced” Hodgkin Lymphoma 
Applying the term “advanced” to a patient with Hodgkin lymphoma implies that there is a 
clear definition of the opposite term, or “limited” disease. Precise, universally accepted 
definitions do not exist for either term as applied to Hodgkin lymphoma.  
Eligibility criteria for clinical trial enrollment are an important source of definitions in 
clinical medicine. For example, the international leaders of Hodgkin lymphoma, the German 
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Hodgkin Study Group (GHSG), included all patients with stage IIIB-IV disease in the HD9 
trial (Diehl et al. 1998), but required that patients with stage IIB disease have one of the 
following: an extralymphatic site, a bulky spleen (diffuse infiltration or > 5 focal lesions), or 
a bulky mediastinum (more than one third of the maximum thoracic diameter). Patients 
with stage IIIA disease were required to have either an erythrocyte sedimentation rate  
>50 mm/hr or ≥ 3 affected lymph node areas. Similarly, two major Italian studies, each 
comparing ABVD with other regimens, enrolled patients with stage IIB along with stage III-
IV disease, although one study uses the term “intermediate and advanced” (Gobbi et al. 
2005) and the other “unfavorable” rather than “advanced”(Viviani et al. 2011). Studies 
comparing MOPP with ABVD (Canellos et al. 1992) or ABVD with hybrid regimens (Duggan 
et al. 2003) in North America have included only stage III and IV patients.  
In order to more easily compare results of studies performed all over the globe, the Hodgkin 
lymphoma community should insist upon homogeneity across clinical trials. In spite of the 
fact that there may be prognostic rationale for including patients with “B” symptoms or 
bulky disease with stage III and IV patients, it is probably more important to have 
uniformity across clinical trials internationally. It is reasonable to reserve the term 
“advanced” Hodgkin lymphoma for stage III and IV patients regardless of disease bulk, B 
symptoms, or any other adverse prognostic factor. Patients with adverse features and stage I 
or II disease would fall into a category of “limited unfavorable”.  
3. Role of combination chemotherapy 
Combination chemotherapy for advanced Hodgkin lymphoma was initially developed by 
Vincent DeVita at the National Cancer Institute (NCI) in response to the initial successes in 
childhood leukemia treatment with combinations of agents. MOMP (mechlorethamine, 
vincristine, methotrexate, prednisone) was the initial combination regimen developed. Once 
procarbazine was developed sufficiently, it replaced methotrexate and the regimen was 
termed MOPP (DeVita et al. 1978). In a landmark study on the results of MOPP, 81 percent 
of stage III/IV Hodgkin lymphoma patients achieved a complete remission, a roughly four-
fold higher response rate than with single agents, and the remission duration, when 
compared retrospectively, was increased approximately ten-fold over single agents alone 
(Devita, Serpick, and Carbone 1970). Ultimately, MOPP was shown in a prospective fashion 
to be superior to single agent nitrogen mustard in a small, randomized trial conducted by 
the Southeastern Cancer Group. One hundred eight patients with stage III or IV Hodgkin 
lymphoma were randomized between MOPP and mechlorethamine given biweekly, and 
patients receiving MOPP were found to have superior complete remission rates and overall 
survival (Huguley et al. 1975). From that time on, combination chemotherapy for advanced 
Hodgkin lymphoma became standard, and comparisons between various combination 
regimens ensued. 
The Cancer and Leukemia Group B (CALGB) performed a randomized comparison amongst 
four different combination chemotherapy regimens: the four-drug combinations were BOPP 
(mechlorethamine substituted with BCNU) and MOPP, and the three-drug combinations 
were BOP (procarbazine eliminated) and OPP (BCNU or mechlorethamine eliminated). This 
study demonstrated superiority of four-drug over three-drug combinations, it highlighted 
the importance of the alkylating agents mechlorethamine and procarbazine, and it further 
solidified the role of four-drug combinations for treating Hodgkin lymphoma (Nissen et al. 
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1979). Interestingly, MOPP and BOPP were equivalent regimens, which demonstrated that 
BCNU and mechlorethamine may have equivalent efficacy. Similarly, a comparison of 
LOPP (lomustine replaces mechlorethamine) with MOPP demonstrated equal efficacy as 
well, further demonstrating that nitrosureas could substitute for alkylating agents in 
treatment of this disease (Hancock 1986).  
In summary, combination chemotherapy became standard on the basis a landmark study of 
MOPP therapy developed at the NCI, with formal confirmation of superiority over single 
agents in one randomized trial. Combination chemotherapy with four drugs was superior to 
three drugs. MOPP, with an alkylating agent meclorethamine, although equivalent in 
efficacy to nitrosurea-containing combinations, was likely favored by most experts in the 
field due to the short and long-term side effects associated with nitrosureas. 
4. ABVD as gold standard 
MOPP combination chemotherapy for advanced Hodgkin lymphoma resulted in twenty to 
thirty percent of patients failing to achieve a complete remission and only fifty percent of 
patients being cured with risks of both sterility and secondary malignancies such as acute 
leukemia (Bonadonna, Valagussa, and Santoro 1986; Longo et al. 1991). Bonadonna Gianni 
developed the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen in order to 
salvage MOPP failures (Bonadonna et al. 1975). In an initial Italian study comparing three 
cycles of ABVD or MOPP with receipt of radiotherapy in both arms, ABVD was superior 
with a seven-year overall survival of 77.4 percent versus 67.9 percent for MOPP (Santoro et 
al. 1987). ABVD therapy became solidified as the gold standard after a landmark three-arm 
CALGB study, which compared ABVD with MOPP and an alternating regimen, 
MOPP/ABVD. The study demonstrated five-year failure-free survival rates of 61 percent for 
ABVD, 50 percent with MOPP, and 65 percent for alternating MOPP/ABVD (Canellos et al. 
1992). The toxicity profile of ABVD was more favorable than either the alternating regimen 
or MOPP, and therefore ABVD became the standard combination chemotherapy regimen 
for advanced Hodgkin lymphoma. 
Interest in the Goldie and Coldman hypothesis (Goldie and Coldman 1979), which 
hypothesized that early introduction of all active agents for a disease would prevent the 
development of resistant clones, led to three major studies comparing hybrid and 
alternating regimens of MOPP and ABVD. No advantage in overall survival was found with 
the hybrid regimens (Connors et al. 1997; Sieber et al. 2002; Viviani et al. 1996). An 
important US Intergroup trial dampened further interest in hybrid regimens by 
demonstrating equivalent efficacy ABVD over a MOPP/ABV hybrid, with a similar failure-
free survival and overall survival at five years but a better toxicity profile of the ABVD 
regimen (Duggan et al. 2003). The solidification of ABVD as the true gold standard would 
take place in the 1990 and 2000’s, in which ABVD became the comparator arm for most 
randomized clinical trials. 
5. The emergence of escalated BEACOPP 
The group with a lead role in the advancement of Hodgkin therapy, the GHSG, developed 
the escalated BEACOPP regimen initially through mathematical modeling of tumor growth 
and chemotherapy effects, (Hasenclever, Loeffler, and Diehl 1996) which led to a pilot 
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clinical trial in which doses of cytotoxic agents were increased in a stepwise fashion (Tesch 
et al. 1998). Escalated BEACOPP, the new dose dense regimen relative to COPP/ABVD and 
dose intense regimen relative to standard BEACOPP, was tested against these two regimens 
in the HD9 clinical trial. Ten year follow-up of that study, in which seventy percent of 
patients received additional radiotherapy, demonstrated statistically and clinically 
significant superiority of escalated BEACOPP over COPP/ABVD and standard BEACOPP 
in terms of freedom from treatment failure rate (82, 70, and 64 percent, respectively) and 
overall survival rate (86, 80, and 75 percent, respectively) (Engert et al. 2009).  
BEACOPP, given in different schedules than the German standard of eight escalated cycles, 
has also been compared with other regimens in two prospective, randomized, Italian 
studies. The HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial was initially designed 
as a toxicity trial to compare rates of leucopenia between three arms: a BEACOPP regimen 
(consisting of four escalated cycles and two standard cycles), a CEC regimen, and ABVD 
(Federico et al. 2009). Once the study centers became comfortable with BEACOPP 
administration, which requires the greatest attention and familiarity in the initial cycles, the 
trial was changed to a primary endpoint of failure-free survival. With a median follow-up of 
forty-one months and a suggestion of lower median dose intensity of BEACOPP delivered 
and resulting lower rates of grade III/IV hematologic toxicity compared with the escalated 
BEACOPP arm of the HD9 trial, the five-year estimated rates of failure-free survival were 78 
and 65 percent in the arms of interest, BEACOPP and ABVD, respectively, which reached 
both clinical and statistical significance. The five-year estimated overall survival 
demonstrated numerical superiority of BEACOPP over ABVD with rates of 92 versus 84 
percent, although this failed to meet statistical significance. In a second recently published 
Italian study, conducted in a similar time period as the HD2000 study, four cycles of 
escalated BEACOPP plus four cycles of standard BEACOPP were compared with ABVD 
with a primary endpoint of freedom from first progression (Viviani et al. 2011). With a 
median follow-up of sixty-one months, the estimated seven-year rate of freedom from first 
progression was 85 percent in the BEACOPP group versus 73 percent in the ABVD group. 
The primary endpoint importantly achieved both statistical and clinical significance. 
Counter to this, the secondary endpoints, which did not have statistical power, were overall 
survival and rate of freedom from second progression. These endpoints were 84 and 82 
percent in the ABVD arm, respectively, versus 89 and 88 percent in the BEACOPP arm, and 
they did not reach statistical significance. Details of exact dose intensity were not provided, 
and one could certainly debate, in spite of the author’s conclusions, the relevance of a five 
percent difference in overall survival, which numerically favored the BEACOPP program. 
The final analysis of the HD12 trial (Diehl et al. 2008), a comparison of eight cycles of 
escalated BEACOPP with four escalated cycles followed by four standard cycles of 
BEACOPP, demonstrates statistical equivalence at five year follow-up between the arms, 
with the eight escalated cycles being numerically superior and still the gold standard 
comparator arm for the HD15 study. The HD15 trial (Kobe et al. 2008) compares eight 
escalated cycles of BEACOPP with six escalated cycles of BEACOPP or eight cycles of 
fourteen day compressed BEACOPP. The results of this study, as well as the results of a 
global study comparing four cycles of escalated BEACOPP followed by four cycles of 
baseline BEACOPP with eight cycles of ABVD (European Organization for Research and 
Treatment of Cancer 2002), are eagerly anticipated.  
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6. Other chemotherapy regimens 
Stanford V is a regimen incorporating twelve total weeks of alternating weekly cycles of 
myelotoxic and nonmyelotoxic polychemotherapy followed by liberal irradiation of 36 Gy to 
sites > 5 cm or macroscopic splenic disease (Bartlett et al. 1995). It was originally designed at 
Stanford although the chemotherapy backbone was likely drawn from the VACOPB 
regimen designed in Vancouver for non-Hodgkin lymphoma (O'Reilly et al. 1991). Stanford 
V was initially compared with ABVD and a regimen called MOPPEBVCAD by the 
Intergruppo Italiano Linfomi. Focusing on the Stanford V and ABVD arms, the primary 
endpoint of failure-free survival at five years was 76 perecent with Stanford V versus 89 
percent with ABVD, with overall survival of 82 percent versus 90 percent, respectively 
(Gobbi et al. 2005). The trial has been criticized for utilizing radiotherapy differently than 
the original Stanford V report, as 66 versus 89 percent of patients, respectively, received 
radiotherapy. Sites > 6 cm rather than >5 cm were irradiated, and radiotherapy occurred 4-6 
weeks rather than 2-4 weeks post-chemotherapy (so called optional versus adjuvant 
radiotherapy). More recently, a large Intergroup study was reported which compared 
Stanford V with six to eight cycles of ABVD. Somewhat unrealistically, the trial was 
designed to detect a 33 percent reduction in the failure-free survival hazard rate with 
Stanford V versus ABVD, and the failure-free survival at five years with Stanford V was 71 
versus 73 percent with ABVD with 87 and 88 percent overall survival rates, respectively 
(Gordon et al. 2010). This trial further solidifies ABVD as the standard polychemotherapy 
regimen in advanced Hodgkin lymphoma, and is still the comparator arm for further 
investigational work.   
Other polychemotherapy regimens which have been the subject of prospective, randomized 
investigation in advanced Hodgkin lymphoma which have not gained widespread appeal 
include: MEC, CHLVPP/EVA, and VAPEC-B. MEC, or MOPPEBVCAD (a regimen 
consisting of: mechlorethamine, lomustine, vindesine, melphalan, prednisone, 
epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin), was compared with 
Stanford V and ABVD in an Italian study, with all arms receiving optional radiotherapy. 
MEC provided similar disease control as ABVD with similar rates of freedom from first 
progression, although the grade III-IV toxicity rates, particularly hematologic toxicity, were 
higher with MEC than ABVD (Gobbi et al. 2005). Therefore, given the better balance of 
efficacy and toxicity afforded by ABVD, MEC fell out of favor. A United Kingdom/Italian 
study compared the hybrid regimen CHLVPP/EVA to VAPEC-B (Radford et al. 1997), an 
abbreviated 11 week polychemotherapy regimen similar to VACOP-B or Stanford V. 
CHLVPP/EVA resulted in a superior three year disease-free and overall survival, with rates 
of 82 and 89 percent versus 62 and 79 percent, respectively for VAPEC-B. When British 
investigators compared ABVD with CHLVPP/EVA or a similar regimen, 
CHLVPP/PABLOE, the three year event-free survival and overall survival were similar, and 
ABVD was better tolerated (Johnson et al. 2005). Since that study, these hybrid 
polychemotherapy regimens have not been utilized. 
In summary of chapters five and six, there is still controversy regarding the optimal 
chemotherapy approach in untreated Hodgkin lymphoma patients. In spite of the two 
“negative” Italian studies, and considering the difference in patient numbers between those 
studies and HD9, it is reasonable to treat patients with advanced Hodgkin lymphoma with 
either escalated BEACOPP or ABVD. Stanford V can be considered in selected patients, 
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recognizing that it has never shown superiority over ABVD or a similar regimen. Further 
refinement of chemotherapy for advanced Hodgkin lymphoma, utilizing both PET/CT 
guidance and monoclonal antibodies, is likely to occur in the future.  
7. Role of radiotherapy 
Radiotherapy is a treatment modality that is believed to be non-crossresistant with standard 
combination chemotherapy (DeVita 2008). Its use can be considered in several contexts in 
advanced Hodgkin lymphoma: as an adjuvant therapy after complete remission is obtained 
with chemotherapy, integrated as combined modality therapy, or utilized as a definitive 
modality when response to chemotherapy is unsatisfactory. 
The first use, as an adjuvant after complete response with polychemotherapy, was assessed 
in four randomized studies. Two studies compared radiotherapy with observation, and two 
studies compared radiotherapy with two additional cycles of chemotherapy. The Southwest 
Oncology Group randomized three hundred and twenty two patients with stage III or IV 
Hodgkin lymphoma who achieved a complete remission by computed tomographic 
assessment after six cycles of MOP-BAP between observation or low-dose (2000 cGy to 
lymph nodes, 1000-1500 cGy to other organs) involved field radiotherapy (IFRT). With a 
median follow-up of eight years, there were no statistically significant differences in relapse-
free or overall survival (Fabian et al. 1994). The GHSG randomized patients with stage III or 
IV disease in complete remission by computed tomographic assessment after six cycles of 
COPP/ABVD to two more cycles of chemotherapy or low-dose (20 Gy) IFRT, and this study 
demonstrated no difference in relapse rate between the two arms (Diehl et al. 1995). A 
GELA study assessed the role of more extensive radiotherapy (subtotal nodal or total) 
versus two more cycles of chemotherapy in stage III/IV patients having achieved a 
complete or very good partial remission (≥ 75% size reduction) with six cycles of either 
MOPP/ABV or ABVPP. With a median follow-up of forty-eight months, the five year 
disease-free survival was 79 percent for the radiotherapy versus 74 percent for continued 
chemotherapy (Ferme et al. 2000). In the largest trial to determine the role of IFRT in stage 
III/IV Hodgkin lymphoma, four hundred twenty-one patients with computed tomogram 
complete remission after MOPP/ABV polychemotherapy were randomly assigned to 
observation versus IFRT. With a median follow-up of seventy-nine months, the five year 
event-free and overall survival rates were 84 percent and 91 percent in the observation 
group, respectively versus 79 percent and 85 percent in the IFRT group, which 
demonstrated that there is no role for IFRT in advanced Hodgkin lymphoma patients who 
achieve a complete remission with polychemotherapy (Aleman et al. 2003).  
The second use, as an integrated therapy with chemotherapy, implies that radiotherapy is a 
pre-planned treatment regardless of response. The most common example of this is the 
administration of 36 Gy radiotherapy to patients receiving the Stanford V regimen who have 
sites of disease > 5cm or macroscopic splenic involvement. Unfortunately, radiotherapy 
administered in this context is completely of unproven value, and the harms are certain. For 
example, with intense polychemotherapy such as escalated BEACOPP, the GHSG has been 
able to reduce the percentage of patients on their studies receiving pre-planned 
radiotherapy from nearly 70 percent to approximately 10 percent without loss of efficacy 
and with a clear-cut reduction in the rate of secondary leukemia, from 1.7 to 0.6 percent 
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comparing HD9 data with HD12 data (Diehl et al. 1998; Diehl et al. 2008). Unfortunately, 
many recently completed clinical trials still include pre-planned radiotherapy, such as the 
ECOG 2496 Intergroup study comparing ABVD with Stanford V, which provided 
radiotherapy to all patients on the ABVD arm with bulky mediastinal disease (Gordon et al. 
2010). Fortunately, most of the new generation of clinical trials, such as SWOG 0816 and 
CALGB 50604, which utilize PET/CT to risk stratify patients for subsequent therapeutic 
strategy, only include radiotherapy to patients categorized as high risk with a positive 
PET/CT after a certain number of chemotherapy cycles (Southwest Oncology Group 2011; 
Cancer and Leukemia Group B 2011). 
The third use, with utilization based on an unsatisfactory response to chemotherapy, 
certainly has theoretical appeal in order to improve outcomes of those patients with partial 
response to combination chemotherapy. Many studies include involved field radiotherapy 
for those patients with “residual tumor”, which again has various definitions. Indirect 
justification for this approach is made by analysis of the Aleman study. The cohort of 
patients who were irradiated after achievement of a partial response with chemotherapy 
had five year event-free and overall survivals of 79 and 87 percent, respectively, which 
compared favorably with those patients having achieved a complete response with 
chemotherapy alone, with event-free and overall survivals of 84 and 91 percent, respectively 
(Aleman et al. 2003). An important question is whether a subset of the patients in partial 
response can be spared the additional toxicity of radiotherapy. In a recent analysis of the 
HD15 trial, in which eight cycles of escalated BEACOPP was compared with six cycles of 
escalated BEACOPP or 14 day compressed BEACOPP, thirty-eight percent of patients had 
residual tumor > 2.5 cm at the completion of chemotherapy. Of this patient group, twenty-
one percent had a positive post-therapy PET/CT and seventy-nine percent had a negative 
PET/CT. The patients with a negative PET/CT were observed, and patients with a positive 
PET/CT received IFRT. The 18 month progression-free survival was 95 percent for patients 
who achieved a CR with chemotherapy, 96 percent for patients with > 2.5 cm residual tumor 
with PET/CT negativity who were observed, and 85 percent for PET/CT positive patients 
who received additional IFRT (Kobe et al. 2008). The authors recommend additional study, 
but in the meantime, a reasonable clinical practice would be to omit radiotherapy in those 
patients in complete metabolic remission post-therapy regardless of the initial disease 
features.  
In summary, there is no role for adjuvant radiotherapy in patients who achieve a computed 
tomography defined complete remission based on several randomized studies. There is no 
clear role of a pre-planned chemotherapy plus radiotherapy approach in advanced Hodgkin 
lymphoma, and although preliminary, it appears reasonable to defer decisions about 
radiotherapy until the post-therapy PET/CT is completed. It appears that patients with non-
FDG avid residual tumors can be safely observed, and based on indirect evidence, 
radiotherapy may benefit those with remaining FDG avidity in tumor masses. 
8. Role of autologous hematopoietic stem cell transplantation 
Autologous hematopoietic stem cell transplant has been studied in four separate 
prospective, randomized controlled clinical trials in Hodgkin lymphoma, in two instances in 
upfront consolidation and in two instances in the relapsed setting. 
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First, two studies utilizing transplant as consolidation of upfront polychemotherapy of 
Hodgkin lymphoma will be discussed. In a Scottish and Newcastle Lymphoma Group 
Study, sixty-five patients with “poor risk” disease were administered three cycles of 
PVACE-BOP chemotherapy with or without XRT. Those patients with a good partial or 
complete response were randomized to a melphalan/etoposide-conditioned autologous 
hematopoietic stem cell transplant versus 2 additional cycles of PVACE-BOP chemotherapy 
(Proctor et al. 2002). With a median follow-up of six years, the arms had a similar time to 
treatment failure, 79 percent in the transplant arm versus 85 percent in the non-transplant 
arm. The major conclusion of this study is that for a subset of patients with “poor risk” 
features derived by calculation of a Scottish Newcastle Lymphoma Group prognostic index, 
autologous hematopoietic stem cell transplantation offers no benefit over standard 
chemotherapy if a very good response on computed tomography is obtained after three 
cycles of polychemotherapy. In a second European Intergroup study, the HD 01 trial, one 
hundred sixty-three patients with “poor risk” disease at baseline were randomized after 
four cycles of ABVD or ABVD-like therapy in complete or partial response to a BEAM or 
CVB-conditioned autologous transplant or four additional cycles of chemotherapy (Federico 
et al. 2003). With a median follow-up of 48 months, the five year failure-free survival was 75 
percent in the transplant arm versus 82 percent in the chemotherapy arm. Rates of overall 
survival were 88 percent in each arm. Although the transplant conditioning regimens 
utilized were different, both trials have similar features, such as attempting to identify a 
poor-risk subset of patients in spite of different criteria used. Additionally, an abbreviated 
course of chemotherapy was utilized prior to the randomization of continued chemotherapy 
versus transplant. Both trials only randomized patients with a response to chemotherapy, 
were small in number, and obtained similar results. Based on these data, there appears to be 
no role for performing autologous transplantation in previously untreated Hodgkin 
lymphoma patients with poor risk features who achieve a response on computed 
tomography imaging.  
Two prospective randomized trials of autologous transplant have been conducted in 
patients with relapsed Hodgkin lymphoma. In the first trial, British investigators 
randomized forty patients with both relapsed and refractory “high risk” disease to either a 
chemotherapy regimen, mini-BEAM, or a BEAM-conditioned autologous transplant without 
details of exact number of chemotherapy courses given. The event-free survival at three 
years was 53 percent in the BEAM group versus 10 percent in the mini-BEAM group (Linch 
et al. 1993). The three year overall survival rate favored the BEAM group but did not achieve 
statistical significance. In the second study, German investigators randomized one hundred 
sixty-one patients with relapsed Hodgkin lymphoma to four cycles of Dexa-BEAM versus 2 
cycles of Dexa-BEAM followed by a BEAM-conditioned autologous transplant (Schmitz et 
al. 2002). The three year estimated freedom from treatment failure was significantly better at 
55 percent in the transplant arm versus 34 percent in the chemotherapy alone arm, while the 
overall survival did not reach statistical significance, with a rate of 71 percent in the 
transplant arm versus 65 percent in the chemotherapy alone arm. In spite of the lack of 
overall survival improvement, the disease-free survival improvement demonstrated in the 
above studies has lead to international acceptance that relapsed Hodgkin lymphoma is a 
definite indication for autologous hematopoietic stem cell transplantation. 
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A small number of refractory patients were included in the British transplant trial, and 
based on their inclusion in that study plus retrospective datasets indicating possible benefit 
of autologous transplant, (Lazarus et al. 1999; Andre et al. 1999; Josting et al. 2000) patients 
with refractory Hodgkin lymphoma who achieve a response or even disease stabilization 
with a salvage chemotherapy regimen can be considered for autologous transplantation.  
Various conditioning regimens for autologous transplantation exist, and the BEAM (BCNU, 
etoposide,cytarabine, melphalan) regimen has been utilized in both randomized trials for 
relapsed/refractory disease. Other reported high-dose chemotherapy regimens include: 
CBV (cyclophosphamide, BCNU, VP-16), CBVP (CBV + cisplatin), Etoposide/Melphalan, 
high dose Melphalan, CCV (cyclophosphamide, CCNU, VP-16), and TLI (total lymphoid 
irradiation)+VP-16/cyclophosphamide). No prospective comparative trials of these 
regimens exist, and due to heterogeneity in parameters reported, even indirect comparison 
is challenging. In a retrospective comparison of two different condidtioning regimens, one 
radiation based with TBI/ cyclophosphamide/etoposide versus a chemotherapy regimen of 
busulfan/melphalan/ thiotepa (Bu/Mel/T), investigators at Fred Hutchinson Cancer 
Center found no difference in efficacy or toxicity of either preparative regimen. Patients who 
had a history of dose-limiting irradiation were treated with the Bu/Mel/T regimen 
preferentially (Gutierrez-Delgado et al. 2003). The BEAM regimen, given its use in the 
randomized trials, is a reasonable choice in the absence of comparative data, and the 
primary clinical issues with use of this regimen are melphalan-related gastrointestinal 
toxicity and BCNU-related pulmonary toxicity, the latter of which requires corticosteroid 
initiation at recognition.  
Further intensification of a single autologous transplant for relapsed/refractory patients has 
been studied, both by utilizing higher doses of standard chemotherapy pre-transplant and 
by the addition of a planned second, or tandem transplant. In the HD-R2 trial, a European 
multicenter (GHSG, EORTC, EBMT, and GEL/TAMO) study for relapsed Hodgkin 
lymphoma, investigators randomized two hundred forty one patients without progressive 
disease after two cycles of DHAP to either a BEAM conditioned autologous transplant or 
sequential high dose chemotherapy with cyclophosphamide 4gm/m2, methotrexate 
8gm/m2, and etoposide 500mg/m2, followed by a BEAM conditioned autologous 
transplant, with IFRT to residual masses > 1.5cm in both arms. With a median follow-up of 
42 months, the three year OS was 87 percent in the standard arm versus 83 percent in the 
high dose sequential arm, with corresponding rates of freedom from treatment failure of 71 
percent and 65 percent, respectively (Josting et al. 2010). The conclusions of the authors, 
based on the largest randomized trial in relapsed Hodgkin lymphoma to date, is that 
sequential high dose chemotherapy has no role and that patient outcomes were quite good 
with two cycles of DHAP followed by a BEAM conditioned transplant. In the prospective, 
multicenter H96 trial conducted by the GELA/SFGM group, investigators studied the role 
of tandem autologous transplant for relapsed/refractory Hodgkin lymphoma patients with 
poor risk disease, defined as primary refractoriness to initial chemotherapy or ≥ 2 risk 
factors of the following: relapse < 12 months from primary therapy, stage III/IV disease at 
relapse, and relapse within a previously irradiated site with combined modality therapy. 
These poor-risk patients received two cycles of chemotherapy followed by a CBV plus 
mitoxantrone or BEAM-conditioned first transplant, with a second transplant with TAM 
(total-body irradiation, cytarabine, melphalan) or BAM (busulfan, cytarabine, melphalan) 
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45-90 days later. On an intent-to-treat basis, with a median follow-up of fifty one months, 
the five year freedom treatment failure and overall survival rates were 46 percent and 57 
percent, respectively (Morschhauser et al. 2008). Seventy percent of poor risk patients 
received a second transplant with a transplant-related mortality of four percent. The authors 
concluded that tandem transplant was an advance in the treatment of poor risk patients 
with partial response to salvage chemotherapy and in those with primary refractory disease, 
given the superior results to historical data of single transplant in those populations.  
In summary, autologous hematopoietic stem cell transplant has no role in the upfront 
treatment of patients with Hodgkin lymphoma. For patients with relapsed disease, it is 
considered the standard of care if chemotherapy sensitivity can be demonstrated. For 
patients with primary refractory disease, autologous transplantation is controversial but a 
small amount of retrospective data indicates a possible benefit. Chemotherapy 
intensification over traditional salvage regimens for relapsed/refractory patients appears to 
have no role, and there is possible benefit in tandem transplant for patients who are at high 
risk for poor outcome with a single autologous transplant. 
9. Salvage therapy for relapsed/refractory disease 
For patients who experience relapse after achievement of a complete response or who do not 
achieve a complete response and have biopsy proven residual Hodgkin lymphoma, 
conventional treatment consists of several cycles of non-crossresistant chemotherapy 
followed by autologous hematopoietic stem cell transplantation. In this chapter, the roles of 
radiotherapy and chemotherapy specifically for relapsed disease will be discussed.  
The use of radiotherapy alone or in combination with salvage chemotherapy in 
relapsed/refractory Hodgkin lymphoma is controversial. Several retrospective reports exist 
on utilizing isolated radiotherapy for patients with relapsed/refractory disease after failure 
of combination chemotherapy. In the largest study, the GHSG found that of the one 
hundred patients in their database treated with radiotherapy alone after failure of 
anthracycline-based chemotherapy, the five-year freedom from treatment failure was 28 
percent with an overall survival of 51 percent (Josting et al. 2005). The authors conclude that 
salvage radiotherapy is a treatment option for a subset of patients without B symptoms but 
with good performance status, limited stage, and late relapses, which effectively excludes 
the majority of Hodgkin lymphoma patients with relapsed disease and all patients with 
refractory disease.  
No reports have compared outcomes of patients who do and do not receive radiotherapy as 
a component of salvage chemotherapy with autologous transplantation, and therefore the 
balance of efficacy and toxicity in this scenario is uncertain. Radiotherapy to “residual 
lesions” after the BEAM-conditioned autologous transplant was recommended in the 
German transplant study in relapsed disease, although too few patients received 
radiotherapy to allow comparison of outcomes to those without radiotherapy. Given that 
the opportunity for cure is greatly diminished in relapsed/refractory Hodgkin lymphoma, 
in spite of an absence of evidence of a definite benefit of radiotherapy, it is reasonable to 
include radiotherapy as part of a treatment regimen that includes salvage chemotherapy 
and autologous transplantation, particularly if the relapse is localized on imaging. Based on 
retrospective information regarding high rates of toxicity when radiotherapy is utilized pre-
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transplant (Tsang et al. 1999), it may be most reasonable to use this modality post-
transplant.  
Salvage chemotherapy is administered to the majority of patients with relapsed/refractory 
Hodgkin lymphoma with the goal of disease reduction or eradication prior to autologous 
transplantation. In fact, in the era of computed tomography, multiple reports document that 
the response to salvage chemotherapy is a major determinant of the outcome of autologous 
transplant (Sureda et al. 2001; Gutierrez-Delgado et al. 2003; Martin et al. 2001) and that the 
degree of response is associated with the progression-free survival at five years (Sirohi et al. 
2008). 
An ideal salvage regimen has an excellent response rate, non-overlapping organ toxicities 
with the primary regimen, and preserves the ability to mobilize and collect hematopoietic 
stem cells. Because initial treatment of Hodgkin lymphoma nearly always consists of 
anthracycline and bleomycin therapy, and because autologous transplant is the usual goal, 
which is a stress on the cardiopulmonary system, salvage therapy choices are typically made 
to limit cardiopulmonary toxicity.  
Many different salvage polychemotherapy regimens have been utilized in the past, and all 
studies have been phase II investigations with heterogeneous patient populations with 
relapsed/refractory disease. See Table 1. Because only DEXA-BEAM and mini-BEAM 
regimens have been used pre-transplant in randomized clinical trials, the purist would 
utilize these regimens at the exclusion of other choices in spite of a toxic death rate between 
two to five percent. In one-hundred forty four patients, the DEXA-BEAM regimen resulted 
in a complete response rate of 27 percent, a partial response rate of 54 percent, and a toxic 
death rate of 5 percent (Schmitz, 2002). In fifty-five patients, the mini-BEAM regimen 
produced a complete response rate of 49 percent, a partial response rate of 33 percent, a 
toxic death rate of 2 percent, and in another cohort of patients, 82 percent collected ≥ 2 x 106 
CD34 cells/kg (Martin et al. 2001; Kuruvilla et al. 2006). 
The platinum-based salvage regimens include ESHAP (etoposide, solumedrol, high-dose 
cytarabine, and cisplatin), ASHAP (doxorubicin, solumedrol, high-dose cytarabine, and 
cisplatin), DHAP (dexamethasone, cytarabine, and cisplatin), and GDP (gemcitabine, 
dexamethasone, and cisplatin). ASHAP as a salvage regimen has limited applicability given 
that most patients will have anthracycline exposure during initial treatment. In twenty-three 
patients, the GDP regimen was reported to have a complete response rate of 17 percent, 
partial response rate of 52 percent, no toxic deaths, and 97 percent of patients collected ≥ 2 x 
106 CD34 cells/kg. (Baetz et al. 2003; Kuruvilla et al. 2006). In twenty-two patients given the 
ESHAP regimen, the complete response rate was 41 percent, partial response rate 32 
percent, toxic death rate 4 percent, with no stem cell collection data provided (Aparicio et al. 
1999). In a report on one hundred two patients administered DHAP on an every two week 
schedule, the complete response rate was 21 percent, partial response rate 68 percent, and 
toxic death rate zero without collection data provided (Josting, Rudolph, et al. 2002). 
Of the ifosfamide-based salvage regimens, two of the regimens are worth mention, ICE 
(ifosfamide, carboplatin, etoposide) and IGEV (ifosfamide, gemcitabine, vinorelbine, 
prednisolone). The ICE regimen, developed at Memorial Sloan-Kettering in an effort to reduce 
the nonhematologic toxicity of cisplatin-based regimens, resulted in a complete response rate 
of 26 percent, partial response rate of 59 percent, a toxic death rate of zero, and 86 percent of 
the sixty-five patients studied achieved a collection of ≥ 2 x 106 CD34 cells/kg (Moskowitz et 
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al. 2001). In a report of ninety-one patients given the IGEV regimen, the complete response rate 
was 54 percent, partial response rate 37 percent, a toxic death rate of zero, and 98.7 percent 
achieved a stem cell collection of ≥ 3 x 106 CD34 cells/kg (Santoro, 2007).  
In spite of the lack of comparative data, the ICE, IGEV, and GDP regimens appear to have 
the most favorable balance of the three key factors of response, low toxic death rate, and 
stem cell preservation. The ICE regimen is typically administered in the inpatient setting 
with the other two regimens given in an outpatient setting. Individual patient factors, such 
as pre-existing neuropathy or renal dysfunction, do play an important role in the final 
choice of a salvage combination chemotherapy regimen.  
In summary, the role of radiotherapy, particularly isolated radiotherapy, in the management 
of relapsed Hodgkin lymphoma remains uncertain, and the standard of care is salvage 
combination chemotherapy for an arbitrary number of cycles followed by high dose 
preparative chemotherapy with autologous hematopoietic stem cell transplantation. Given the 
poorer results in salvage than upfront treatment, and the belief that disease is ultimately the 
greater problem than therapy toxicity in this younger patient population, erring on the side of 
consolidative radiotherapy post-transplant in those with limited stage relapse is reasonable.  
 
Regimen Composition CR, ORR% 
Toxic Death 
Rate
Stem Cell 
Colllection 
DEXA-BEAM 
Dexamethasone, 
BCNU, Etoposide, Ara-
C, Melphalan
27, 81 5 NR 
 
Mini-BEAM 
 
 
 
GDP 
 
 
 
ESHAP 
 
 
 
 
DHAP 
 
 
 
ICE 
 
 
 
IGEV 
BCNU, Etoposide, Ara-
C, Melphalan 
 
Gemcitabine, 
Dexamethasone, 
Cisplatin 
 
Etoposide, SoluMedrol, 
Ara-C, Cisplatin 
 
 
Dexamethasone, Ara-
C, Cisplatin 
 
 
Ifosfamide, 
Carboplatin, Etoposide
 
Ifosfamide, 
Gemcitabine, 
Vinorelbine, 
Prednisone
49, 82 
 
 
 
17, 69 
 
 
 
41, 73 
 
 
 
21, 89 
 
 
 
26, 85 
 
 
 
54, 91 
 
2 
 
 
 
0 
 
 
 
4 
 
 
 
0 
 
 
 
0 
 
 
 
0 
 
82 percent ≥ 2 x 106 
CD34+ cells/kg 
 
97 percent ≥ 2 x 106 
CD34+ cells/kg 
 
NR 
 
 
 
NR 
 
 
 
86 percent ≥ 2 x 106 
CD34+ cells/kg 
 
98 percent ≥ 3 x 106 
CD34+ cells/kg 
 
Table 1. Comparison of salvage chemotherapy regimens for relapsed/refractory Hodgkin 
lymphoma. 
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10. Role of allogeneic hematopoietic stem cell transplantation 
Patients with Hodgkin lymphoma who relapse after autologous hematopoietic stem cell 
transplantation have a very poor long term outlook, with several series documenting a low 
rate of long term survivors (Crump 2008; Constans et al. 2004). In a retrospective Spanish 
analysis of patients who relapsed after autologous transplant, the progression free survival 
and overall survival were 23 percent and 35 percent at three years, respectively. 
Investigators at Wayne State retrospectively studied this patient population, and found an 
approximate 10 percent survival rate at four years post autologous transplant, and similar 
results were found in a series of patients from Memorial Sloan Kettering (Varterasian et al. 
1995). Two findings were interesting in the Memorial series: one, nearly all of the long term 
survivors received a reduced-intensity allogeneic hematopoietic stem cell transplant, and 
second, the reduced-intensity allogeneic transplant appeared to be of little benefit to patients 
who relapsed within six months of the autologous transplant (Moskowitz et al. 2009).  
Allogeneic transplants are typically divided into myeloablative versus reduced-intensity or 
nonmyeloablative depending on the intensity of the preparative regimen. Multiple reports on 
the efficacy and toxicity of myeloablative transplants for Hodgkin Lymphoma exist in the 
literature, and all are consistent in demonstrating an unacceptably high rate of treatment-
related mortality. In a retrospective assessment of one hundred patients in the International 
Bone Marrow Transplant Registry (IBMTR), eighty-nine percent of the patients had active 
disease at the time of transplant, with a resulting three year disease-free survival rate of 15 
percent, overall survival of 21 percent, and probabilities of acute and chronic graft-versus-host 
disease of 35 and 45 percent, respectively (Gajewski et al. 1996). The authors appropriately 
concluded that myeloablative sibling transplants have little role in the treatment of Hodgkin 
lymphoma. In a similar retrospective analysis, the European Bone Marrow Transplant (EBMT) 
registry retrospectively analyzed the outcomes of one hundred sixty-seven allogeneic 
transplants in patients with Hodgkin lymphoma, and found an actuarial overall survival of 24 
percent at four years, primarily related to a 52 percent procedure-related mortality at four 
years (Peniket et al. 2003). Again, the authors appropriately concluded that the toxicity of 
allogeneic procedures would have to be reduced before broader applicability would be 
realized. In a retrospective matched case analysis by the EBMT of forty five allogeneic and 
forty five autologous transplants, it was found that the four year probability of survival, 
progression-free survival, relapse, and non-relapse mortality were 25, 15, 61, and 48 percent 
after allogeneic transplant with corresponding figures of 37, 24, 81, and 27 percent after 
autologous transplant (Milpied et al. 1996). The authors concluded that the positive effect of a 
decreased relapse rate with allogeneic transplant is offset by the toxicity and transplant-related 
mortality. Hence, multiple retrospective series of myeloablative allogeneic transplantation in 
Hodgkin lymphoma reached the same conclusion, namely the toxicity outweighs the small 
benefit from the treatment. 
The applicability of allogeneic hematopoietic stem cell transplantation in a wide spectrum of 
hematologic disorders has been broadened by the advent of reduced-intensity conditioning, 
in which lower, non or partially myeloablative doses of chemotherapy either with or 
without radiotherapy are administered prior to infusion of allogeneic stem cells. 
A convincing graft versus Hodgkin lymphoma effect was demonstrated after reduced-
intensity allogeneic transplantation (Peggs et al. 2005). Several reports of long term follow-
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up of reduced-intensity allogeneic transplant demonstrate the curative potential of this 
procedure. In an EBMT retrospective analysis, with a median follow-up of seventy-five 
months for survivors, 18 percent were progression free at five years with an overall survival 
rate of 20 percent (Sureda et al. 2008). In another report with a median follow-up of forty-
nine months, the estimated progression-free survival was 34 percent and overall survival 51 
percent at five years.  
In summary, myeloablative allogeneic transplantation appears to have little role in the 
treatment of Hodgkin lymphoma given the morbidity and mortality associated with the 
procedure. However, reduced-intensity allogeneic transplantation is a reasonable 
consideration in patients with a matched donor who have relapsed following an autologous 
transplant given the curative potential of the procedure in a desperate clinical situation.   
11. Prognostic factors along the disease spectrum of advanced disease 
Prognostic factors are measurements on individuals performed at or soon after diagnosis 
which gives likely outcome of the disease. Although far less useful to the clinician than 
predictive factors, which are directly influenced by treatment, prognostic factors can be used 
as guides in choosing an appropriate treatment strategy. Prognostic factors for advanced 
Hodgkin lymphoma are fairly well established because treatment over time has been more 
uniform and relapses are higher in frequency than for limited stage Hodgkin lymphoma.  
The most useful information for prognosis in advanced Hodgkin lymphoma comes from a 
large retrospective analysis, a so-called tour de force, performed by German investigators 
(Hasenclever and Diehl 1998). They analyzed baseline characteristics and determined the 
outcomes of five thousand one hundred forty-one patients with primarily stage III/IV 
disease treated with ABVD or similar regimens in multiple centers. The authors found, on 
multivariate analysis that the prognosis of patients with advanced Hodgkin lymphoma 
depended on seven baseline characteristics including: age, gender, total leukocyte count, 
lymphocyte percentage or absolute number, albumin, hemoglobin, and stage. Because the 
relative risk for poorer outcome was similar between factors, the authors created the 
International Prognostic Score (IPS) for advanced Hodgkin lymphoma by simply adding 
each factor for a total score of 0-7: 1 point for age>45, male gender, total leukocyte count 
>15,000 cells/mcL, absolute lymphocyte count <600 cells/mcL or lymphocyte percentage 
<8%, albumin <4 g/dL, hemoglobin <10.5 g/dL, and stage IV. Higher scores indicate a 
worse prognosis, and this information was confirmed in an independent data set. Although 
many other reports exist describing other adverse prognostic features in advanced Hodgkin 
lymphoma, the significance of other factors in relation to the IPS is uncertain, and the IPS 
appears to be the principal prognostic tool for patients at baseline.  
The risk factors in relapsed Hodgkin lymphoma are more controversial than in untreated 
disease, but the GHSG contributed a large retrospective study analyzing the risk factors for 
poor outcome in four hundred twenty-two relapsed patients. They developed a prognostic 
score based on three factors: time to relapse, clinical stage, and presence of anemia (Josting, 
Franklin, et al. 2002).  
More recently, interest has grown to better refine baseline prognosis with information on 
disease response with therapy, which has consistently shown to be an important factor 
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when degree of response in untreated or relapsed patients is considered. In other words, 
attainment of complete response, as is the case for most hematologic malignancies, is the 
name of the game for Hodgkin lymphoma. Computed tomography, an extremely valuable 
tool for assessment of anatomic structures, has been the traditional assessment tool for 
response in lymphomas, with criteria for definition of complete and partial response clearly 
delineated (Cheson et al. 1999). Given that lymph node size may correlate less well with 
viable cancer than functional imaging with positron emission tomography, it is now 
generally accepted that either fusion PET/CT or PET and CT are superior to CT alone at 
baseline and post-therapy restaging. Given the superiority in re-staging, interest grew in 
obtaining information from PET at earlier and earlier timepoints, in order to utilize that 
information, the so-called interim PET, for treatment decisions. A major report in this arena 
was a retrospective study by an Italian group of patients with advanced Hodgkin 
lymphoma treated with ABVD or similar regimens, who underwent PET scanning after two 
cycles of treatment, and outcomes were compared between PET positive and negative 
patients, with a comparison with IPS to delineate the most robust prognostic factor. The 
results of PET essentially made results of IPS inconsequential, with a clear difference 
between patients with positive and negative PET, with progression-free survivals of 12.8 
versus 95 percent, respectively, and only PET was significant for prognosis in multivariate 
analysis, which included the IPS (Gallamini et al. 2007). Based on this result and promising 
information from other similar yet smaller reports, most current clinical trials in Hodgkin 
lymphoma are determining in a prospective fashion the prognostic value of PET/CT. 
Additionally, many are also testing risk-adapted therapeutic strategies to improve 
outcomes.  
Not only has PET scanning been found to be prognostic in untreated patients as a re-staging 
strategy, but it has been utilized prior to autologous or allogeneic transplant (Svoboda et al. 
2006; Jabbour et al. 2007), with a clear improvement in transplant outcome in those patients 
with negative functional imaging prior to transplant.     
12. Promising therapies of the future 
There are many exciting therapies on the horizon for patients with advanced Hodgkin 
lymphoma. Although none of the treatments discussed below have made their way into the 
armamentarium for the newly diagnosed patient, the treatments below have been selected 
as they appear to be associated with the most promise and are furthest in development in 
relapsed/refractory Hodgkin lymphoma. The most important future therapies, in the 
opinion of the author, are brentuximab vedotin, rituximab, bendamustine, panobinostat, 
and lenalidomide. See Table 2. Each will be discussed in further detail in this section. 
Brentuximab vedotin, long known as SGN-35, and now known as Adcetris after the United 
States Food & Drug Administration granted accelerated approval of this antibody-drug 
conjugate on August 19, 2011, appears to be an important new treatment option in Hodgkin 
lymphoma. The approval was long awaited by those who had seen multiple failures of 
unconjugated monoclonal antibodies to CD30, a protein expressed on the surface of Reed 
Sternberg cells. To specifically enhance clinical anti-tumor activity, the antitubulin agent 
monomethyl auristatin E was attached to the CD30-specific monoclonal antibody cAC10 by 
an enzyme-cleavable dipeptide linker (Hamblett et al. 2004). It is indicated for patients with 
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relapsed or refractory Hodgkin’s lymphoma after failure of autologous stem cell transplant 
or at least two prior multi-agent chemotherapy regimens in patients who are not transplant 
candidates. The accelerated approval was based on a single-arm, multicenter clinical trial in 
one hundred two patients with multiply relapsed or refractory Hodgkin lymphoma to 
evaluate the objective response rate as a single agent. Patients were treated with 1.8 mg/kg 
intravenously over thirty minutes every three weeks. The primary efficacy endpoint, the 
overall response rate, was achieved in 73 percent of patients with a complete remission rate 
of 32 percent. The median duration of response was 6.7 months (Chen et al. 2010). The most 
common adverse events were peripheral sensory neuropathy, fatigue, nausea, neutropenia, 
diarrhea, and pyrexia, with most events being grade 1 or 2, and no grade 5 events occurred 
on treatment. The response rate associated with this agent given as monotherapy is highly 
encouraging, and further study of this compound is anxiously anticipated. Currently, it is 
being investigated in a phase I clinical trial in combination with ABVD chemotherapy 
(Seattle Genetics 2011), and in a phase III randomized clinical trial, AETHERA, in which its 
use is compared with placebo in “high risk” Hodgkin lymphoma patients post-autologous 
transplant (Seattle Genetics 2011). This compound appears to represent a major advance in 
the treatment of Hodgkin lymphoma given the unprecedented response rates in multiply 
relapsed and highly refractory patient populations.  
Rituximab is an intravenous chimeric monoclonal antibody directed at the CD20 antigen, 
which is present only on a minority of Reed Sternberg or Hodgkin cells of classic Hodgkin 
lymphoma (Schmid et al. 1991). In spite of this, a pilot study of rituximab was performed in 
patients with relapsed/refractory classic Hodgkin lymphoma regardless of CD20 status 
(Younes et al. 2003). In that study, five of twenty-two patients (22 percent) responded with 
36 percent achieving stable disease with expected excellent tolerability. Further study by the 
same investigators at MD Anderson focused on the addition of rituximab to ABVD therapy. 
One hundred four patients with newly diagnosed advanced disease were treated with six 
weekly doses of rituximab during ABVD chemotherapy, and their outcomes were compared 
with historical patients treated with ABVD. The five year event-free survival with ABVD 
was 66 percent versus a projected 87 percent for R-ABVD with a median follow-up time of 
five years, and all IPS risk groups seemed to benefit from the addition of rituximab 
(Copeland et al. 2009). This study generated great excitement, and it is the springboard for 
two major ongoing advanced Hodgkin lymphoma studies. In the HD18 trial of the GHSG, 
patients with PET positivity after two cycles of escalated BEACOPP are randomly assigned 
to further chemotherapy with or without rituximab (University of Cologne 2011). The 
second trial is a phase II study randomizing patients to R-ABVD versus ABVD at a single 
institution (M.D. Anderson Cancer Center 2011). In summary, rituximab appears to be a 
promising step forward with little toxicity in the treatment of advanced classic Hodgkin 
lymphoma, and the results of the above studies are eagerly anticipated. 
In contrast to classic Hodgkin lymphoma, the neoplastic cells, known as the lymphocyte 
predominant cells of nodular lymphocyte predominant Hodgkin lymphoma, express CD20 
strongly. Importantly, several studies indicate that rituximab as a single agent in both 
previously treated and untreated patients carries a very high response rate in this subtype of 
Hodgkin lymphoma (Ekstrand et al. 2003; Schulz et al. 2008), and it is reasonable, given the 
rarity of advanced disease with nodular lymphocyte predominant Hodgkin lymphoma, to 
utilize rituximab in combination with chemotherapy for patients with this disease.   
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Bendamustine, an intravenous bifunctional alkylator and nucleoside analogue, was 
synthesized in East Germany in 1963 but only recently its use has become popularized in the 
United States with FDA approval for CLL and indolent NHL occurring in 2008. Its activity 
in Hodgkin lymphoma was well known to the East Germans, and recently Memorial Sloan 
Kettering investigators put this compound on the international map in Hodgkin lymphoma. 
Benadmustine was administered at a dose of 120mg/m2 day one and two of twenty-eight 
day cycles with pegylated filgrastim support in a single center phase II study of relapsed 
Hodgkin lymphoma patients post-transplant or transplant-ineligible. Although major 
conclusions are limited by the small evaluable patient number of sixteen, the overall 
response rate of 75 percent and CR rate of 38 percent are encouraging, along with twelve of 
sixteen patients with response becoming eligible for a non-myeloablative allogeneic 
transplant. Currently, an Italian study is investigating in a phase I/II trial its efficacy and 
toxicity combined with another promising agent for Hodgkin lymphoma, lenalidomide 
(Fondazione Giovanni Pascale).  
Another promising new compound in the treatment of advanced Hodgkin lymphoma is the 
oral histone deacetylase inhibitor, panobinostat. Preliminary evidence of activity in 
refractory Hodgkin lymphoma was demonstrated in a small phase I/II prospective, 
multicenter study of thirteen patients, and a remarkable response rate of 38 percent was 
found with computed tomography criteria, with 58 percent of patients responding by 
positron emission tomography criteria (Dickinson et al. 2009). The principal dose-limiting 
toxicity with panobinostat is thrombocytopenia, unfortunately, as many patients with 
relapsed disease have impaired bone marrow reserve. Forty percent of patients in this study 
developed grade 3/4 thrombocytopenia. In a large multicenter, prospective, phase II study, 
40 mg of panobinostat was administered orally three times per week every week in 21 day 
cycles to one hundred twenty-nine relapsed/refractory patients (Sureda et al. 2010). 
Responses were observed in 27 percent of patients with 82 percent of patients having stable 
disease or better. This phase II study, with very promising response rates in a large number 
of heavily pre-treated patients, has led to a number of current studies in Hodgkin 
lymphoma, including a phase III study of panobinostat versus placebo for maintenance 
therapy (Novartis Pharmaceuticals 2011), and a phase I study in combination with ICE and a 
planned follow-on phase II study of panobinostat plus ICE versus ICE alone (M.D. 
Anderson Cancer Center 2011).       
Lenalidomide is an oral immunomodulatory agent with an uncertain mechanism of action 
that appears to have activity in a broad range of hematopoietic malignancies. The use of 
lenalidomide was empiric, and in an initial small cohort of twelve patients with multiply 
relapsed Hodgkin lymphoma treated in Germany, it was found to be safe with no toxicity 
greater than grade two. Additionally, it was efficacious with a response rate of fifty percent 
with at least disease stabilization in all patients (Boll et al. 2010). In a prospective phase II 
Canadian study, fifteen patients with relapsed/refractory disease were enrolled and given 
lenalidomide 25 mg orally day 1-21 of 28 day cycles. The overall response rate was 14 
percent with at least disease stabilization in 64 percent of patients. Hematologic toxicity was 
the predominant toxicity seen, with 29 percent of patients with grade 3/4 neutropenia and 
thrombocytopenia (Kuruvilla et al. 2008). In a similar study conducted by United States 
investigators, thirty-eight patients were enrolled on a prospective phase II study of 
relapsed/refractory patients with lenalidomide administered in the same fashion as the 
prior study (Fehniger et al. 2009). Of thirty-five evaluable patients, the overall response rate 
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was 17 percent with stabilization of disease for greater than six months in 34 percent. Grade 
3/4 toxicity was primarily hematologic, with neutropenia being the most common at 40 
percent of patients. The authors concluded that activity was seen and continuous dosing 
and utilization in combinations would be reasonable in the future. Currently, lenalidomide 
is under evaluation in phase I studies in combination with benadmustine (Fondazione 
Giovanni Pascale 2011), AVD (University of Cologne 2011), and as maintenance post-
autologous transplant (Washington University School of Medicine). 
In summary, there are a number of agents with promising activity in relapsed Hodgkin 
lymphoma currently in development. Further study will define their ultimate role, but the 
favorable toxicity profile and encouraging reports of activity of the monoclonal antibodies 
make these compounds of high interest for further investigation.  
 
Compound Mechanism Route 
CR, ORR% 
Median 
Response 
Duration 
Current Status 
Brentuximab 
Vedotin 
Monoclonal Antibody-
drug conjugate (anti-
CD30) 
Intravenous 
32%, 78% 
 
6.7 months 
FDA approved, 
relapsed/ refractory 
Ongoing phase I, III 
studies 
 
Rituximab 
 
 
 
Bendamustine 
 
 
 
Panobinostat 
 
 
 
Lenalidomide 
 
Chimeric monoclonal 
antibody (anti-CD20) 
 
 
Bifunctional 
Alkylator/ nucleoside 
analog 
 
Histone deacetylase 
inhibitor 
 
 
Immunomodulator 
(many mechanisms) 
 
Intravenous
 
 
 
Intravenous
 
 
 
Oral 
 
 
 
Oral 
 
5%, 22% 
 
7.8 months 
 
38%, 75% 
 
2.6 months 
 
4%, 27% 
 
6.9 months 
 
3%, 17% 
 
4.5 months 
 
Ongoing phase II, 
III studies 
 
 
Ongoing phase I/II 
study 
 
 
Ongoing phase I, III 
studies 
 
 
Ongoing phase I/II 
studies 
Table 2. Promising Drugs in Development for Hodgkin lymphoma. 
13. Case studies 
In this section, several case scenarios will be presented, and management will be discussed, 
which integrates material covered in prior sections.  
Case 1. A twenty-three year old otherwise healthy Caucasian female was diagnosed with stage 
IIIB nodular sclerosis Hodgkin lymphoma after an excisional biopsy was performed due to left 
neck adenopathy. The mediastinum was bulky at diagnosis. The IPS was 1 for anemia. She 
was treated with six cycles of ABVD at full dose and schedule and achieved a complete 
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metabolic remission on PET/CT. Fifteen months later, PET/CT revealed asymptomatic FDG 
avid mediastinal adenopathy, and thoracotomy with excisional biopsy revealed a relapse of 
nodular sclerosis Hodgkin lymphoma. Hemoglobin was normal. She was treated with ICE for 
three cycles followed by stem cell mobilization and collection and autologous hematopoietic 
stem cell transplantation with BEAM conditioning. She receives 36 Gy to the mediastinum two 
months post-transplant and is alive and well seven years post-transplant.  
Case 1 Discussion. This young woman was given a standard of care for advanced Hodgkin 
lymphoma at diagnosis, and ABVD was favored in this instance over escalated BEACOPP 
for fertility preservation, as the patient expressed interest in maintaining fertility. The 
author’s preference is to enroll patients with advanced Hodgkin lymphoma on a clinical 
trial if possible, and currently this would be the SWOG 0816 at the author’s institution. The 
lack of thoracic radiotherapy was reasonable given the PET/CT defined complete remission. 
This patient’s relapse can be classified as low risk by the Josting score as she had none of the 
the adverse factors which include: early relapse, advanced stage at relapse, and anemia. 
Therefore, she again received a standard of care including: choice of salvage regimen, 
decision for autologous transplant, and choice of preparative regimen. The exact value of 
thoracic radiotherapy administration post-transplant is uncertain but reasonable given the 
bulky disease of mediastinum initially and the limited stage relapse. The increased risk of 
solid cancers including breast and lung with thoracic radiotherapy should be discussed with 
the patient, and long term follow-up should include counseling on smoking cessation, breast 
and skin examination regularly, breast mammography, and vaccinations yearly for 
influenza, every five years for pneumococcus, and every ten years for tetanus/diphtheria 
(Connors 2005). 
Case 2. A thirty-five year old otherwise healthy African American male is diagnosed with 
stage IVA mixed cellularity Hodgkin lymphoma after excisional biopsy is performed of a 
right inguinal mass. Bone marrow involvement is present at diagnosis and FDG avid lesions 
are seen in the liver. His International Prognostic Score is 5 with the following risk factors: 
low albumin, low lymphocyte count, low hemoglobin, stage IV, and male gender. There are 
no bulky sites of disease. He is treated with escalated BEACOPP for six cycles and achieves 
a complete remission by PET/CT post-therapy. His PET/CT after two cycles of escalated 
BEACOPP was negative as well. Five months later, he has biopsy proven relapsed Hodgkin 
lymphoma after left axillary lymph node enlargement prompts an excisional biopsy. His 
relapse stage is III, and GDP is administered for three cycles. He achieves a partial metabolic 
remission on PET/CT with a negative bone marrow biopsy. Organ function is preserved, 
and he receives a BEAM-conditioned autologous transplant. He suffers another biopsy-
proven relapse with stage III disease seven months post autologous transplant. He is treated 
with IGEV salvage chemotherapy for three cycles, and achieves another partial metabolic 
response. Given that his organ function is preserved, he undergoes a reduced-intensity 
allogeneic hematopoietic stem cell transplant with Flu/Bu conditioning. He is alive three 
years post-allogeneic transplant with mild chronic graft versus host disease.  
Case 2 Discussion. This young man was given an appropriate initial therapy, escalated 
BEACOPP, given his high risk disease. In fact, escalated BEACOPP is reasonable for any 
advanced Hodgkin lymphoma patient <60 years without pregnancy, HIV, or abnormal 
organ function regardless of IPS. He was given six cycles rather than the current standard of 
eight cycles established by the GHSG. Would he still have suffered a relapse if given eight 
cycles, is it appropriate to administer six cycles in this situation, and is it appropriate to 
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obtain interim PET/CT scans outside the context of clinical trials? The answer to each of 
these questions is obviously controversial. The author believes that it is reasonable to 
perform interim PET/CT scans off study, and to make certain therapeutic decisions on the 
basis of those scans. Because the PET/CT was negative after two cycles, the author believes 
that it was a reasonable clinical decision to administer six rather than eight total cycles. 
Although impossible at present to know, the author believes that it is unlikely that two more 
cycles of escalated BEACOPP would have cured the case patient. Again, it is the author’s 
strong preference to obtain further prospective data regarding interim PET/CT and therapy 
adjustment, which is why the optimal treatment for current patients with Hodgkin 
lymphoma is a clinical trial. The choice of GDP as salvage chemotherapy is very reasonable, 
as is the choice to take a patient in partial remission to a BEAM conditioned autologous 
transplant. Given at least three adverse prognostic factors associated with this relapse, 
which are: early relapse, relapse after high intensity initial chemotherapy, and partial rather 
than complete metabolic response pre-transplant, the author believes, even though 
randomized data are not available, that performing a tandem transplant as in the H96 study 
would have been reasonable in this patient. Once relapse after autologous transplant occurs, 
prognosis is poor and this case example illustrates that a reduced-intensity allogeneic 
hematopoietic stem cell transplant can be curative in this setting. In addition to the chronic 
adverse health effects associated with allogeneic transplant, Hodgkin lymphoma survivors 
do have persistent challenges in health related quality of life, particularly in regards to 
chronic fatigue (Baxi and Matasar 2010). This patient would likely benefit from 
multidisciplinary follow-up care including input from psychiatry and social work.          
14. Conclusion 
There are many unanswered questions the clinician faces in the care of the individual 
patient with advanced Hodgkin lymphoma throughout the course of the disease. 
Polychemotherapy with regimens such as ABVD or escalated BEACOPP for six to eight 
cycles are the standard of care for newly diagnosed patients, and the role of radiotherapy is 
uncertain. Refinement of morbidity and mortality related to chemotherapy and 
radiotherapy may be possible in the future with a sincere commitment of physicians to 
enroll patients on the current generation of clinical trials testing PET/CT directed strategies. 
Several newer agents are likely to be incorporated into polychemotherapy in the future 
based on promising results in the relapsed setting. The goal of therapy in the short term is a 
PET/CT without FDG avidity, or complete remission, and in the long term a cure. For most 
patients with relapsed or refractory Hodgkin lymphoma, polychemotherapy for 
approximately three cycles followed by autologous hematopoietic stem cell transplantation 
is the current standard of care. Radiotherapy should be considered in the relapsed setting to 
optimize curative potential of treatment in spite of the potential morbidity and lack of clear 
evidence base. Reduced intensity allogeneic hematopoietic stem cell transplantation should 
be considered as the primary curative treatment modality in those patients without 
significant comorbidity who relapse after autolgous transplantation.  
15. Acknowledgments 
I would like to acknowledge my family, who I love including my wife Ellen, sons Luke, 
Gabriel, and Michael, as well as my parents, Dennis and Patricia. Without these people in 
my life, this work would not be possible.  
www.intechopen.com
 
State of the Art Therapy of Advanced Hodgkin Lymphoma 
 
167 
I would like to also acknowledge my mentors who give me daily guidance as physicians 
and friends, and were kind enough to review my work shortly before the deadline, Paul J. 
Petruska, M.D. and Friedrich G. Schuening, M.D. 
I would like to also acknowledge my patients and their families. Hopefully I help you as 
much as you teach me. 
I would also like to acknowledge Carol Murray and Kim Lipsey, who provided valuable 
assistance in referencing this chapter. 
16. References 
Aleman, B. M., J. M. Raemaekers, U. Tirelli, R. Bortolus, M. B. van 't Veer, M. L. Lybeert, J. J. 
Keuning, P. Carde, T. Girinsky, R. W. van der Maazen, R. Tomsic, M. Vovk, A. van 
Hoof, G. Demeestere, P. J. Lugtenburg, J. Thomas, W. Schroyens, K. De Boeck, J. W. 
Baars, J. C. Kluin-Nelemans, C. Carrie, M. Aoudjhane, D. Bron, H. Eghbali, W. G. 
Smit, J. H. Meerwaldt, A. Hagenbeek, A. Pinna, M. Henry-Amar, Research 
European Organization for, and Group Treatment of Cancer Lymphoma. 2003. 
Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 
(24):2396-406. 
Andre, M., M. Henry-Amar, J. L. Pico, P. Brice, D. Blaise, M. Kuentz, B. Coiffier, P. 
Colombat, J. Y. Cahn, M. Attal, J. Fleury, N. Milpied, G. Nedellec, P. Biron, H. Tilly, 
J. P. Jouet, and C. Gisselbrecht. 1999. Comparison of high-dose therapy and 
autologous stem-cell transplantation with conventional therapy for Hodgkin's 
disease induction failure: a case-control study. Societe Francaise de Greffe de 
Moelle. J Clin Oncol 17 (1):222-9. 
Aparicio, J., A. Segura, S. Garcera, A. Oltra, A. Santaballa, A. Yuste, and M. Pastor. 1999. 
ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 10 (5):593-5. 
Baetz, T., A. Belch, S. Couban, K. Imrie, J. Yau, R. Myers, K. Ding, N. Paul, L. Shepherd, J. 
Iglesias, R. Meyer, and M. Crump. 2003. Gemcitabine, dexamethasone and cisplatin 
is an active and non-toxic chemotherapy regimen in relapsed or refractory 
Hodgkin's disease: a phase II study by the National Cancer Institute of Canada 
Clinical Trials Group. Ann Oncol 14 (12):1762-7. 
Bartlett, N. L., S. A. Rosenberg, R. T. Hoppe, S. L. Hancock, and S. J. Horning. 1995. Brief 
chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage 
Hodgkin's disease: a preliminary report. J Clin Oncol 13 (5):1080-8. 
Baxi, S. S., and M. J. Matasar. 2010. State-of-the-art issues in Hodgkin's lymphoma 
survivorship. Curr Oncol Rep 12 (6):366-73. 
Boll, B., P. Borchmann, M. S. Topp, M. Hanel, K. S. Reiners, A. Engert, and R. Naumann. 
2010. Lenalidomide in patients with refractory or multiple relapsed Hodgkin 
lymphoma. Br J Haematol 148 (3):480-2. 
Bonadonna, G., P. Valagussa, and A. Santoro. 1986. Alternating non-cross-resistant 
combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-
year results. Ann Intern Med 104 (6):739-46. 
Bonadonna, G., R. Zucali, S. Monfardini, M. De Lena, and C. Uslenghi. 1975. Combination 
chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and 
imidazole carboxamide versus MOPP. Cancer 36 (1):252-9. 
Cancer and Leukemia Group B. 2011. Chemotherapy Based on Positron Emission 
Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin 
www.intechopen.com
 
Hodgkin's Lymphoma 
 
168 
Lymphoma. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2011- [cited 2011 Sept 15]. Available from: 
 http://clinicaltrials.gov/show/NCT01132807. 
Canellos, G. P., J. R. Anderson, K. J. Propert, N. Nissen, M. R. Cooper, E. S. Henderson, M. R. 
Green, A. Gottlieb, and B. A. Peterson. 1992. Chemotherapy of advanced Hodgkin's 
disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 
(21):1478-84. 
Chen, Robert, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, 
Richard Klasa, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. 
Kennedy, Eric L. Sievers, and Anas Younes. 2010. Results of a Pivotal Phase 2 Study 
of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin 
Lymphoma. ASH Annual Meeting Abstracts 116 (21):283-. 
Cheson, B. D., S. J. Horning, B. Coiffier, M. A. Shipp, R. I. Fisher, J. M. Connors, T. A. Lister, 
J. Vose, A. Grillo-Lopez, A. Hagenbeek, F. Cabanillas, D. Klippensten, W. 
Hiddemann, R. Castellino, N. L. Harris, J. O. Armitage, W. Carter, R. Hoppe, and 
G. P. Canellos. 1999. Report of an international workshop to standardize response 
criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working 
Group. J Clin Oncol 17 (4):1244. 
Connors, J. M. 2005. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 23 
(26):6400-8. 
Connors, J. M., P. Klimo, G. Adams, B. F. Burns, I. Cooper, R. M. Meyer, S. E. O'Reilly, J. 
Pater, I. Quirt, A. Sadura, C. Shustik, J. Skillings, S. Sutcliffe, S. Verma, S. Yoshida, 
and B. Zee. 1997. Treatment of advanced Hodgkin's disease with chemotherapy--
comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and 
ABVD: a report from the National Cancer Institute of Canada clinical trials group. J 
Clin Oncol 15 (4):1638-45. 
Constans, Mireia, Anna Sureda, Reyes Arranz, Maria Dolores Caballero, Juan Jose Lahuerta, 
Juan Carlos Hernandez-Boluda, Maria Jesus Vidal, Jose Garcia-Larana, Jose Rifon, 
Josep Maria Ribera, Pascual Fernandez-Abellan, Jose Maria Moraleda, Maria Teresa 
Bernal, Maria Victoria Mateos, Maria Martin-Mateos, Rafael Cordoba, Javier 
Garcia-Conde, Jorge Sierra, Eulogio Conde, and for the Spanish Cooperative Group 
GEL/TAMO. 2004. Prognostic Factors and Long-Term Outcome for Patients with 
Hodgkin's Lymphoma Who Relapse after an Autologous Stem Cell 
Transplantation. ASH Annual Meeting Abstracts 104 (11):1649-. 
Copeland, Amanda R, Yumei Cao, Michelle Fanale, Luis Fayad, Peter McLaughlin, Barbara 
Pro, Fredrick Hagemeister, Jorge Romaguera, Felipe Samaniego, Alma Rodriguez, 
and Anas Younes. 2009. Final Report of a Phase-II Study of Rituximab Plus ABVD 
for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin 
Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical 
Data. ASH Annual Meeting Abstracts 114 (22):1680-. 
Crump, M. 2008. Management of Hodgkin lymphoma in relapse after autologous stem cell 
transplant. Hematology Am Soc Hematol Educ Program:326-33. 
DeVita, V. T., Jr., B. J. Lewis, M. Rozencweig, and F. M. Muggia. 1978. The chemotherapy of 
Hodgkin's disease: past experiences and future directions. Cancer 42 (2 Suppl):979-
90. 
Devita, V. T., Jr., A. A. Serpick, and P. P. Carbone. 1970. Combination chemotherapy in the 
treatment of advanced Hodgkin's disease. Ann Intern Med 73 (6):881-95. 
www.intechopen.com
 
State of the Art Therapy of Advanced Hodgkin Lymphoma 
 
169 
DeVita, Vincent T. Lawrence Theodore S. Rosenberg Steven A. 2008. DeVita, Hellman, and 
Rosenberg's cancer : principles & practice of oncology: Wolters Kluwer/Lippincott 
Williams & Wilkins. 
Dickinson, M., D. Ritchie, D. J. DeAngelo, A. Spencer, O. G. Ottmann, T. Fischer, K. N. 
Bhalla, A. Liu, K. Parker, J. W. Scott, M. Bishton, and H. M. Prince. 2009. 
Preliminary evidence of disease response to the pan deacetylase inhibitor 
panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147 (1):97-
101. 
Diehl, V., J. Franklin, D. Hasenclever, H. Tesch, M. Pfreundschuh, B. Lathan, U. Paulus, M. 
Sieber, J. U. Rueffer, M. Sextro, A. Engert, J. Wolf, R. Hermann, L. Holmer, U. 
Stappert-Jahn, E. Winnerlein-Trump, G. Wulf, S. Krause, A. Glunz, K. von Kalle, H. 
Bischoff, C. Haedicke, E. Duehmke, A. Georgii, and M. Loeffler. 1998. BEACOPP, a 
new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD 
in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial 
of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16 (12):3810-21. 
Diehl, V., M. Loeffler, M. Pfreundschuh, U. Ruehl, D. Hasenclever, H. Nisters-Backes, M. 
Sieber, K. Smith, H. Tesch, W. Geilen, and et al. 1995. Further chemotherapy versus 
low-dose involved-field radiotherapy as consolidation of complete remission after 
six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. 
German Hodgkins' Study Group (GHSG). Ann Oncol 6 (9):901-10. 
Diehl, Volker, Heinz Haverkamp, Rolf Peter Mueller, Hans Theodor Eich, Hans Konrad 
Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony Ho, Lothar Kanz, 
Richard Greil, Wolfgang Hiddemann, and Andreas Engert. 2008. Eight Cycles of 
BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 
4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in 
Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised 
HD12 Trial of the German Hodgkin Study Group (GHSG). ASH Annual Meeting 
Abstracts 112 (11):1558-. 
Duggan, D. B., G. R. Petroni, J. L. Johnson, J. H. Glick, R. I. Fisher, J. M. Connors, G. P. 
Canellos, and B. A. Peterson. 2003. Randomized comparison of ABVD and 
MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an 
intergroup trial. J Clin Oncol 21 (4):607-14. 
Ekstrand, B. C., J. B. Lucas, S. M. Horwitz, Z. Fan, S. Breslin, R. T. Hoppe, Y. Natkunam, N. 
L. Bartlett, and S. J. Horning. 2003. Rituximab in lymphocyte-predominant 
Hodgkin disease: results of a phase 2 trial. Blood 101 (11):4285-9. 
Engert, A., V. Diehl, J. Franklin, A. Lohri, B. Dorken, W. D. Ludwig, P. Koch, M. Hanel, M. 
Pfreundschuh, M. Wilhelm, L. Trumper, W. E. Aulitzky, M. Bentz, M. Rummel, O. 
Sezer, H. K. Muller-Hermelink, D. Hasenclever, and M. Loffler. 2009. Escalated-
dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's 
lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27 
(27):4548-54. 
European Organization for Research and Treatment of Cancer. 2002. Comparison of Two 
Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage 
IV Hodgkin's Lymphoma. In ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2011- [cited 2011 Sept 15]. Available from: 
http://clinicaltrials.gov/show/NCT00049595. 
www.intechopen.com
 
Hodgkin's Lymphoma 
 
170 
Fabian, C. J., C. M. Mansfield, S. Dahlberg, S. E. Jones, T. P. Miller, E. Van Slyck, P. N. 
Grozea, F. S. Morrison, C. A. Coltman, Jr., and R. I. Fisher. 1994. Low-dose involved 
field radiation after chemotherapy in advanced Hodgkin disease. A Southwest 
Oncology Group randomized study. Ann Intern Med 120 (11):903-12. 
Federico, M., M. Bellei, P. Brice, M. Brugiatelli, A. Nagler, C. Gisselbrecht, L. Moretti, P. 
Colombat, S. Luminari, F. Fabbiano, N. Di Renzo, A. Goldstone, A. M. Carella, and 
Ebmt Gisl Anzlg Sfgm Gela Intergroup HD01 Trial. 2003. High-dose therapy and 
autologous stem-cell transplantation versus conventional therapy for patients with 
advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 
(12):2320-5. 
Federico, M., S. Luminari, E. Iannitto, G. Polimeno, L. Marcheselli, A. Montanini, A. La Sala, 
F. Merli, C. Stelitano, S. Pozzi, R. Scalone, N. Di Renzo, P. Musto, L. Baldini, G. 
Cervetti, F. Angrilli, P. Mazza, M. Brugiatelli, P. G. Gobbi, and H. D. Gruppo 
Italiano per lo Studio dei Linfomi Trial. 2009. ABVD compared with BEACOPP 
compared with CEC for the initial treatment of patients with advanced Hodgkin's 
lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi 
Trial. J Clin Oncol 27 (5):805-11. 
Fehniger, Todd A, Sarah Larson, Kathryn Trinkaus, Marilyn J Siegel, Amanda F Cashen, 
Kristie A Blum, Timothy S. Fenske, David D Hurd, Andre Goy, John F. DiPersio, 
and Nancy L Bartlett. 2009. A Phase II Multicenter Study of Lenalidomide in 
Relapsed or Refractory Classical Hodgkin Lymphoma. ASH Annual Meeting 
Abstracts 114 (22):3693-. 
Ferme, C., C. Sebban, C. Hennequin, M. Divine, P. Lederlin, J. Gabarre, A. Ferrant, D. 
Caillot, D. Bordessoule, P. Brice, I. Moullet, F. Berger, and E. Lepage. 2000. 
Comparison of chemotherapy to radiotherapy as consolidation of complete or good 
partial response after six cycles of chemotherapy for patients with advanced 
Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 
trial. Blood 95 (7):2246-52. 
Fondazione Giovanni Pascale. 2011. A Phase 1/2 Study of Lenalidomide in Combination 
With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma 
(LEBEN). In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2011- [cited 2011 Sept 15]. Available from: 
http://clinicaltrials.gov/ct2/show/NCT01412307?term=NCT01412307&rank=1. 
Gajewski, J. L., G. L. Phillips, K. A. Sobocinski, J. O. Armitage, R. P. Gale, R. E. Champlin, R. 
H. Herzig, D. D. Hurd, S. Jagannath, J. P. Klein, H. M. Lazarus, P. L. McCarthy, Jr., 
S. Pavlovsky, F. B. Peterson, P. A. Rowlings, J. A. Russell, S. M. Silver, J. M. Vose, P. 
H. Wiernik, M. M. Bortin, and M. M. Horowitz. 1996. Bone marrow transplants 
from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14 (2):572-
8. 
Gallamini, A., M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. 
Di Raimondo, F. D'Amore, A. Biggi, U. Vitolo, C. Stelitano, R. Sancetta, L. Trentin, 
S. Luminari, E. Iannitto, S. Viviani, I. Pierri, and A. Levis. 2007. Early interim 2-
[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically 
superior to international prognostic score in advanced-stage Hodgkin's lymphoma: 
a report from a joint Italian-Danish study. J Clin Oncol 25 (24):3746-52. 
Gobbi, P. G., A. Levis, T. Chisesi, C. Broglia, U. Vitolo, C. Stelitano, V. Pavone, L. Cavanna, 
G. Santini, F. Merli, M. Liberati, L. Baldini, G. L. Deliliers, E. Angelucci, R. 
www.intechopen.com
 
State of the Art Therapy of Advanced Hodgkin Lymphoma 
 
171 
Bordonaro, M. Federico, and Linfomi Intergruppo Italiano. 2005. ABVD versus 
modified stanford V versus MOPPEBVCAD with optional and limited 
radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final 
results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin 
Oncol 23 (36):9198-207. 
Goldie, J. H., and A. J. Coldman. 1979. A mathematic model for relating the drug sensitivity 
of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 (11-12):1727-33. 
Gordon, Leo I, Fanxing Hong, Richard I Fisher, Nancy L. Bartlett, Joseph M. Connors, 
Randy D. Gascoyne, Henry Wagner, Patrick J Stiff, Bruce D. Cheson, Mary 
Gospodarowicz, Ranjana Advani, Brad Kahl, Jonathan W. Friedberg, Kristie A. 
Blum, Thomas M. Habermann, Joseph Tuscano, Richard Hoppe, and Sandra J. 
Horning. 2010. A Randomized Phase III Trial of ABVD Vs. Stanford V +/- 
Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's 
Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve 
Oncology Group (E2496). ASH Annual Meeting Abstracts 116 (21):415-. 
Gutierrez-Delgado, F., L. Holmberg, H. Hooper, S. Petersdorf, O. Press, R. Maziarz, D. 
Maloney, T. Chauncey, F. Appelbaum, and W. Bensinger. 2003. Autologous stem 
cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa 
compared to a radiation-based regimen. Bone Marrow Transplant 32 (3):279-85. 
Hamblett, K. J., P. D. Senter, D. F. Chace, M. M. Sun, J. Lenox, C. G. Cerveny, K. M. Kissler, 
S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, D. L. Meyer, and J. A. Francisco. 2004. 
Effects of drug loading on the antitumor activity of a monoclonal antibody drug 
conjugate. Clin Cancer Res 10 (20):7063-70. 
Hancock, B. W. 1986. Randomised study of MOPP (mustine, Oncovin, procarbazine, 
prednisone) against LOPP (Leukeran substituted for mustine) in advanced 
Hodgkin's disease. British National Lymphoma Investigation. Radiother Oncol 7 
(3):215-21. 
Hasenclever, D., and V. Diehl. 1998. A prognostic score for advanced Hodgkin's disease. 
International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J 
Med 339 (21):1506-14. 
Hasenclever, D., M. Loeffler, and V. Diehl. 1996. Rationale for dose escalation of first line 
conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's 
Lymphoma Study Group. Ann Oncol 7 Suppl 4:95-8. 
Huguley, C. M., Jr., J. R. Durant, R. R. Moores, Y. K. Chan, R. F. Dorfman, and L. Johnson. 
1975. A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone 
(MOPP) vs. nitrogen mustard in advanced Hodgkin's disease. Cancer 36 (4):1227-40. 
Jabbour, E., C. Hosing, G. Ayers, R. Nunez, P. Anderlini, B. Pro, I. Khouri, A. Younes, F. 
Hagemeister, L. Kwak, and L. Fayad. 2007. Pretransplant positive positron 
emission tomography/gallium scans predict poor outcome in patients with 
recurrent/refractory Hodgkin lymphoma. Cancer 109 (12):2481-9. 
Johnson, P. W., J. A. Radford, M. H. Cullen, M. R. Sydes, J. Walewski, A. S. Jack, K. A. 
MacLennan, S. P. Stenning, S. Clawson, P. Smith, D. Ryder, B. W. Hancock, and L. 
Y. Trial United Kingdom Lymphoma Group. 2005. Comparison of ABVD and 
alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's 
lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial 
(ISRCTN97144519). J Clin Oncol 23 (36):9208-18. 
www.intechopen.com
 
Hodgkin's Lymphoma 
 
172 
Josting, A., J. Franklin, M. May, P. Koch, M. K. Beykirch, J. Heinz, C. Rudolph, V. Diehl, and 
A. Engert. 2002. New prognostic score based on treatment outcome of patients with 
relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's 
lymphoma study group. J Clin Oncol 20 (1):221-30. 
Josting, A., H. Muller, P. Borchmann, J. W. Baars, B. Metzner, H. Dohner, I. Aurer, L. 
Smardova, T. Fischer, D. Niederwieser, K. Schafer-Eckart, N. Schmitz, A. Sureda, J. 
Glossmann, V. Diehl, D. DeJong, M. L. Hansmann, J. Raemaekers, and A. Engert. 
2010. Dose intensity of chemotherapy in patients with relapsed Hodgkin's 
lymphoma. J Clin Oncol 28 (34):5074-80. 
Josting, A., L. Nogova, J. Franklin, J. P. Glossmann, H. T. Eich, M. Sieber, T. Schober, H. D. 
Boettcher, U. Schulz, R. P. Muller, V. Diehl, and A. Engert. 2005. Salvage 
radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a 
retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin 
Oncol 23 (7):1522-9. 
Josting, A., C. Rudolph, M. Reiser, M. Mapara, M. Sieber, H. H. Kirchner, B. Dorken, D. K. 
Hossfeld, V. Diehl, A. Engert, and Centers Participating. 2002. Time-intensified 
dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low 
toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13 
(10):1628-35. 
Josting, A., U. Rueffer, J. Franklin, M. Sieber, V. Diehl, and A. Engert. 2000. Prognostic 
factors and treatment outcome in primary progressive Hodgkin lymphoma: a 
report from the German Hodgkin Lymphoma Study Group. Blood 96 (4):1280-6. 
Kobe, C., M. Dietlein, J. Franklin, J. Markova, A. Lohri, H. Amthauer, S. Klutmann, W. H. 
Knapp, J. M. Zijlstra, A. Bockisch, M. Weckesser, R. Lorenz, M. Schreckenberger, R. 
Bares, H. T. Eich, R. P. Mueller, M. Fuchs, P. Borchmann, H. Schicha, V. Diehl, and 
A. Engert. 2008. Positron emission tomography has a high negative predictive 
value for progression or early relapse for patients with residual disease after first-
line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112 (10):3989-94. 
Kuruvilla, J., T. Nagy, M. Pintilie, R. Tsang, A. Keating, and M. Crump. 2006. Similar 
response rates and superior early progression-free survival with gemcitabine, 
dexamethasone, and cisplatin salvage therapy compared with carmustine, 
etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell 
transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106 (2):353-
60. 
Kuruvilla, John, Diane Taylor, Lisa Wang, Chantale Blattler, Armand Keating, and Michael 
Crump. 2008. Phase II Trial of Lenalidomide in Patients with Relapsed or 
Refractory Hodgkin Lymphoma. ASH Annual Meeting Abstracts 112 (11):3052-. 
Lazarus, H. M., P. A. Rowlings, M. J. Zhang, J. M. Vose, J. O. Armitage, P. J. Bierman, J. L. 
Gajewski, R. P. Gale, A. Keating, J. P. Klein, C. B. Miller, G. L. Phillips, D. E. Reece, 
K. A. Sobocinski, K. van Besien, and M. M. Horowitz. 1999. Autotransplants for 
Hodgkin's disease in patients never achieving remission: a report from the 
Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17 (2):534-45. 
Linch, D. C., D. Winfield, A. H. Goldstone, D. Moir, B. Hancock, A. McMillan, R. Chopra, D. 
Milligan, and G. V. Hudson. 1993. Dose intensification with autologous bone-
marrow transplantation in relapsed and resistant Hodgkin's disease: results of a 
BNLI randomised trial. Lancet 341 (8852):1051-4. 
www.intechopen.com
 
State of the Art Therapy of Advanced Hodgkin Lymphoma 
 
173 
Longo, D. L., P. L. Duffey, V. T. DeVita, Jr., P. H. Wiernik, S. M. Hubbard, J. C. Phares, A. W. 
Bastian, E. S. Jaffe, and R. C. Young. 1991. Treatment of advanced-stage Hodgkin's 
disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin 
Oncol 9 (8):1409-20. 
M.D. Anderson Cancer Center. 2011. Panobinostat Plus Ifosfamide, Carboplatin, and 
Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma. In 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2011- [cited 2011 Sept 15]. Available from: 
 http://clinicaltrials.gov/ct2/show/NCT01169636?term=NCT01169636&rank=1. 
Repeated Author. 2011. Phase II R-ABVD Versus ABVD for Advanced Stage Classical 
Hodgkin Lymphoma. In ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2011- [cited 2011 Sept 15]. Available from: 
http://clinicaltrials.gov/ct2/show/NCT00654732?term=pHASE+II+R-
ABVD+VERSUS+ABVD&rank=1. 
Martin, A., M. C. Fernandez-Jimenez, M. D. Caballero, M. A. Canales, J. A. Perez-Simon, J. 
Garcia de Bustos, L. Vazquez, F. Hernandez-Navarro, and J. F. San Miguel. 2001. 
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for 
relapsed or refractory Hodgkin's disease. Br J Haematol 113 (1):161-71. 
Milpied, N., A. K. Fielding, R. M. Pearce, P. Ernst, and A. H. Goldstone. 1996. Allogeneic 
bone marrow transplant is not better than autologous transplant for patients with 
relapsed Hodgkin's disease. European Group for Blood and Bone Marrow 
Transplantation. J Clin Oncol 14 (4):1291-6. 
Morschhauser, F., P. Brice, C. Ferme, M. Divine, G. Salles, R. Bouabdallah, C. Sebban, L. 
Voillat, O. Casasnovas, A. Stamatoullas, K. Bouabdallah, M. Andre, J. P. Jais, D. 
Cazals-Hatem, C. Gisselbrecht, and Gela Sfgm Study Group. 2008. Risk-adapted 
salvage treatment with single or tandem autologous stem-cell transplantation for 
first relapse/refractory Hodgkin's lymphoma: results of the prospective 
multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 26 (36):5980-7. 
Moskowitz, A. J., M. A. Perales, T. Kewalramani, J. Yahalom, H. Castro-Malaspina, Z. 
Zhang, J. Vanak, A. D. Zelenetz, and C. H. Moskowitz. 2009. Outcomes for patients 
who fail high dose chemoradiotherapy and autologous stem cell rescue for 
relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 146 (2):158-63. 
Moskowitz, C. H., S. D. Nimer, A. D. Zelenetz, T. Trippett, E. E. Hedrick, D. A. Filippa, D. 
Louie, M. Gonzales, J. Walits, N. Coady-Lyons, J. Qin, R. Frank, J. R. Bertino, A. 
Goy, A. Noy, J. P. O'Brien, D. Straus, C. S. Portlock, and J. Yahalom. 2001. A 2-step 
comprehensive high-dose chemoradiotherapy second-line program for relapsed 
and refractory Hodgkin disease: analysis by intent to treat and development of a 
prognostic model. Blood 97 (3):616-23. 
Nissen, N. I., T. F. Pajak, O. Glidewell, J. Pedersen-Bjergaard, L. Stutzman, G. Falkson, J. 
Cuttner, J. Blom, L. Leone, A. Sawitsky, M. Coleman, F. Haurani, C. L. Spurr, J. B. 
Harley, B. Seligman, C. Cornell, Jr., P. Henry, H. J. Senn, K. Brunner, G. Martz, P. 
Maurice, A. Bank, L. Shapiro, G. W. James, and J. F. Holland. 1979. A comparative 
study of a BCNU containing 4-drug program versus MOPP versus 3-drug 
combinations in advanced Hodgkin's disease: a cooperative study by the Cancer 
and Leukemia Group B. Cancer 43 (1):31-40. 
Novartis Pharmaceuticals. 2011. A Phase III Randomized, Double Blind, Placebo Controlled 
Multi-center Study of Panobinostat for Maintenance of Response in Patients With 
www.intechopen.com
 
Hodgkin's Lymphoma 
 
174 
Hodgkin's Lymphoma, edited by C. g. [Internet]. Bethesda (MD): National Library 
of Medicine (US). 2011- [cited 2011 Sept 15]. Available from: 
http://clinicaltrials.gov/ct2/show/NCT01034163?term=NCT01034163&rank=1. 
O'Reilly, S. E., P. Hoskins, P. Klimo, and J. M. Connors. 1991. MACOP-B and VACOP-B in 
diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Annals of 
Oncology 2 (SUPPL. 1):17-23. 
Peggs, K. S., A. Hunter, R. Chopra, A. Parker, P. Mahendra, D. Milligan, C. Craddock, R. 
Pettengell, A. Dogan, K. J. Thomson, E. C. Morris, G. Hale, H. Waldmann, A. H. 
Goldstone, D. C. Linch, and S. Mackinnon. 2005. Clinical evidence of a graft-versus-
Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. 
Lancet 365 (9475):1934-41. 
Peniket, A. J., M. C. Ruiz de Elvira, G. Taghipour, C. Cordonnier, E. Gluckman, T. de Witte, 
G. Santini, D. Blaise, H. Greinix, A. Ferrant, J. Cornelissen, N. Schmitz, A. H. 
Goldstone, and Registry European Bone Marrow Transplantation Lymphoma. 
2003. An EBMT registry matched study of allogeneic stem cell transplants for 
lymphoma: allogeneic transplantation is associated with a lower relapse rate but a 
higher procedure-related mortality rate than autologous transplantation. Bone 
Marrow Transplant 31 (8):667-78. 
Proctor, S. J., M. Mackie, A. Dawson, J. White, R. J. Prescott, H. L. Lucraft, B. Angus, G. H. 
Jackson, A. L. Lennard, A. Hepplestone, and P. R. Taylor. 2002. A population-based 
study of intensive multi-agent chemotherapy with or without autotransplant for 
the highest risk Hodgkin's disease patients identified by the Scotland and 
Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle 
Lymphoma Group study (SNLG HD III). Eur J Cancer 38 (6):795-806. 
Radford, J. A., A. Z. S. Rohatiner, D. J. Dunlop, A. Rossi, W. D. J. Ryder, D. P. Deakin, and et 
al. 1997. Preliminary results of a four-centre randomised trial comparing weekly 
VAPEC-B chemptherapy with the CHLVPP/EVA hybrid regimen in previously 
regimen in previously untreated Hodgkin's disease. Paper read at 
Program/Proceedings, American Society of Clinical Oncology : thirty-third annual 
meeting, May 17-20, 1997, Denver, CO. 
Santoro, A., G. Bonadonna, P. Valagussa, R. Zucali, S. Viviani, F. Villani, A. M. Pagnoni, V. 
Bonfante, R. Musumeci, F. Crippa, and et al. 1987. Long-term results of combined 
chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD 
plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5 (1):27-37. 
Schmid, C., L. Pan, T. Diss, and P. G. Isaacson. 1991. Expression of B-cell antigens by 
Hodgkin's and Reed-Sternberg cells. Am J Pathol 139 (4):701-7. 
Schmitz, N., B. Pfistner, M. Sextro, M. Sieber, A. M. Carella, M. Haenel, F. Boissevain, R. 
Zschaber, P. Muller, H. Kirchner, A. Lohri, S. Decker, B. Koch, D. Hasenclever, A. 
H. Goldstone, V. Diehl, Group German Hodgkin's Lymphoma Study, Blood 
Lymphoma Working Party of the European Group for, and Transplantation 
Marrow. 2002. Aggressive conventional chemotherapy compared with high-dose 
chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed 
chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (9323):2065-71. 
Schulz, H., U. Rehwald, F. Morschhauser, T. Elter, C. Driessen, T. Rudiger, P. Borchmann, R. 
Schnell, V. Diehl, A. Engert, and M. Reiser. 2008. Rituximab in relapsed 
lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial 
by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111 (1):109-11. 
www.intechopen.com
 
State of the Art Therapy of Advanced Hodgkin Lymphoma 
 
175 
Seattle Genetics, Inc. 2011. A Phase 1 Study of Brentuximab Vedotin Combined With Multi-
Agent Chemotherapy for Hodgkin Lymphoma. In ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2011- [cited 2011 Sept 15]. 
Available from:  
 http://clinicaltrials.gov/ct2/show/NCT01060904?term=NCT01060904&rank=1. 
Repeated Author. 2011. A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at 
High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The 
AETHERA Trial). In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2011- [cited 2011 Sept 15]. Available from:  
 http://clinicaltrials.gov/ct2/show/NCT01100502?term=NCT01100502&rank=1. 
Sieber, M., H. Tesch, B. Pfistner, U. Rueffer, B. Lathan, O. Brosteanu, U. Paulus, T. Koch, M. 
Pfreundschuh, M. Loeffler, A. Engert, A. Josting, J. Wolf, D. Hasenclever, J. 
Franklin, E. Duehmke, A. Georgii, K. P. Schalk, H. Kirchner, G. Doelken, R. 
Munker, P. Koch, R. Herrmann, R. Greil, A. P. Anselmo, and V. Diehl. 2002. 
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating 
COPP/ABVD in combination with extended-field radiotherapy in intermediate-
stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma 
Study Group Trial HD5. J Clin Oncol 20 (2):476-84. 
Sirohi, B., D. Cunningham, R. Powles, F. Murphy, T. Arkenau, A. Norman, J. Oates, A. 
Wotherspoon, and A. Horwich. 2008. Long-term outcome of autologous stem-cell 
transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 19 
(7):1312-9. 
Southwest Oncology Group. 2011. A Phase II Trial of Response-Adapted Therapy of Stage 
III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging. In 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2011- [cited 2011 Sept 15]. Available from: 
 http://clinicaltrials.gov/archive/NCT00822120/2011_09_06. 
Sureda, A., R. Arranz, A. Iriondo, E. Carreras, J. J. Lahuerta, J. Garcia-Conde, I. Jarque, M. D. 
Caballero, C. Ferra, A. Lopez, J. Garcia-Larana, R. Cabrera, D. Carrera, M. D. Ruiz-
Romero, A. Leon, J. Rifon, J. Diaz-Mediavilla, R. Mataix, M. Morey, J. M. Moraleda, 
A. Altes, A. Lopez-Guillermo, J. de la Serna, J. M. Fernandez-Ranada, J. Sierra, E. 
Conde, and Group Grupo Espanol de Linformas/Transplante Autologo de Medula 
Osea Spanish Cooperative. 2001. Autologous stem-cell transplantation for 
Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo 
Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative 
Group. J Clin Oncol 19 (5):1395-404. 
Sureda, A., S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. 
Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, M. Gramatzki, D. Niederwieser, N. H. 
Russell, and N. Schmitz. 2008. Reduced-intensity conditioning compared with 
conventional allogeneic stem-cell transplantation in relapsed or refractory 
Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the 
European Group for Blood and Marrow Transplantation. J Clin Oncol 26 (3):455-62. 
Sureda, Anna, Anas Younes, Dina Ben-Yehuda, Tee-Chuan Ong, Jonathan L. Kaufman, 
Christophe Le Corre, Jennifer Gallagher, Angela Shen, and Andreas Engert. 2010. 
Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory 
Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell 
Transplant. ASH Annual Meeting Abstracts 116 (21):419-. 
www.intechopen.com
 
Hodgkin's Lymphoma 
 
176 
Svoboda, J., C. Andreadis, R. Elstrom, E. A. Chong, L. H. Downs, A. Berkowitz, S. M. Luger, 
D. L. Porter, S. Nasta, D. Tsai, A. W. Loren, D. L. Siegel, E. Glatstein, A. Alavi, E. A. 
Stadtmauer, and S. J. Schuster. 2006. Prognostic value of FDG-PET scan imaging in 
lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow 
Transplant 38 (3):211-6. 
Tesch, H., V. Diehl, B. Lathan, D. Hasenclever, M. Sieber, U. Ruffer, A. Engert, J. Franklin, 
M. Pfreundschuh, K. P. Schalk, G. Schwieder, G. Wulf, G. Dolken, P. Worst, P. 
Koch, N. Schmitz, U. Bruntsch, C. Tirier, U. Muller, and M. Loeffler. 1998. 
Moderate dose escalation for advanced stage Hodgkin's disease using the 
bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, 
and prednisone scheme and adjuvant radiotherapy: a study of the German 
Hodgkin's Lymphoma Study Group. Blood 92 (12):4560-7. 
Tsang, R. W., M. K. Gospodarowicz, S. B. Sutcliffe, M. Crump, and A. Keating. 1999. 
Thoracic radiation therapy before autologous bone marrow transplantation in 
relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto 
Autologous BMT Group. Eur J Cancer 35 (1):73-8. 
University of Cologne 2011. AVD-Rev in Elderly Hodgkin Lymphoma Patients. In 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2011- [cited 2011 Sept 15]. Available from: 
 http://clinicaltrials.gov/ct2/show/NCT01056679?term=NCT01056679&rank=1. 
University of Cologne. 2011. HD18 for Advanced Stages in Hodgkins Lymphoma. In 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2011- [cited 2011 Sept 15]. Available from: 
 http://clinicaltrials.gov/ct2/show/NCT00515554?term=NCT00515554&rank=1. 
Varterasian, M., V. Ratanatharathorn, J. P. Uberti, C. Karanes, E. Abella, F. Momin, C. 
Kasten-Sportes, A. Al-Katib, L. Lum, L. K. Heilbrun, and et al. 1995. Clinical course 
and outcome of patients with Hodgkin's disease who progress after autologous 
transplantation. Leuk Lymphoma 20 (1-2):59-65. 
Viviani, S., G. Bonadonna, A. Santoro, V. Bonfante, M. Zanini, L. Devizzi, F. Soncini, and P. 
Valagussa. 1996. Alternating versus hybrid MOPP and ABVD combinations in 
advanced Hodgkin's disease: ten-year results. J Clin Oncol 14 (5):1421-30. 
Viviani, S., P. L. Zinzani, A. Rambaldi, E. Brusamolino, A. Levis, V. Bonfante, U. Vitolo, A. 
Pulsoni, A. M. Liberati, G. Specchia, P. Valagussa, A. Rossi, F. Zaja, E. M. Pogliani, 
P. Pregno, M. Gotti, A. Gallamini, D. Rota Scalabrini, G. Bonadonna, A. M. Gianni, 
Foundation Michelangelo, Linfomi Gruppo Italiano di Terapie Innovative nei, and 
Linfomi Intergruppo Italiano. 2011. ABVD versus BEACOPP for Hodgkin's 
lymphoma when high-dose salvage is planned. N Engl J Med 365 (3):203-12. 
Washington University School of Medicine. 2011. Lenalidomide Maintenance Therapy Post 
Autologous Transplant for Hodgkins Lymphoma. In ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2011- [cited 2011 Sept 15]. 
Available from: http://clinicaltrials.gov/ct2/show/NCT01207921. 
Younes, A., J. Romaguera, F. Hagemeister, P. McLaughlin, M. A. Rodriguez, P. Fiumara, A. 
Goy, S. Jeha, J. T. Manning, Jr., D. Jones, L. V. Abruzzo, and L. J. Medeiros. 2003. A 
pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 
98 (2):310-4. 
www.intechopen.com
Hodgkin's Lymphoma
Edited by Dr. Nima Rezaei
ISBN 978-953-51-0402-5
Hard cover, 272 pages
Publisher InTech
Published online 23, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Hodgkin's Lymphoma is the book consisting of 11 chapters: Recent insights into the biology of Hodgkin's
lymphoma, including historical aspects, epidemiology, pathophysiology, genetic defects, and prognostic
indicators are explained in the intro chapters. After a translational chapter from tumor microenvironment to
immunotherapeutic approach, treatment of early stage, advanced, and refractory Hodgkin's lymphoma are
explained in the following chapters. MALT lymphoma and adverse effects of chemotherapy and radiotherapy
in the affected patients are discussed in the subsequent chapters, while the final chapter is focused on
survivorship in Hodgkin's lymphoma. The book is intended to present recent advances in the pathophysiology
of Hodgkin's lymphoma as well as practical approach to diagnosis and management in clinical practice, which
is hoped to be welcomed by the physicians, who wish to learn more about Hodgkin's lymphoma.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Mark J. Fesler (2012). State of the Art Therapy of Advanced Hodgkin Lymphoma, Hodgkin's Lymphoma, Dr.
Nima Rezaei (Ed.), ISBN: 978-953-51-0402-5, InTech, Available from:
http://www.intechopen.com/books/hodgkin-s-lymphoma/state-of-the-art-therapy-of-advanced-hodgkin-
lymphoma
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
